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Limited long-term patency of synthetic small diameter vascular grafts has driven 
considerable research to address their two main failure modes: thrombosis and re-occlusion of the 
vessel due to intimal hyperplasia. To address these limitations, our lab has created a multilayered 
graft with a hydrogel inner layer that promotes post-implantation endothelialization for initial and 
sustained thromboresistance and an electrospun outer layer with arterial compliance matching to 
limit intimal hyperplasia. In this work, we provide improvements in cellular interactions, outer 
layer mechanics, and hydrogel design to increase the graft’s potential for long term patency. 
First, we further characterized cellular interactions with the inner layer that promote 
thromboresistance upon endothelialization. To optimize these interactions, we investigated specific 
integrin targeting utilizing designer proteins and their effect on endothelial cell hemostatic 
regulation. Elucidation of this relationship allows for tailoring thromboresistance of our inner layer 
as well as other blood contacting devices. We further improved the graft by increasing outer layer 
compliance matching and elucidated the intrinsic relationship between compliance mismatch and 
the development of intimal hyperplasia. We first fabricated grafts of increasing compliance while 
maintaining safe burst pressures and suture retention strength by modulating electrospinning 
parameters without altering graft chemistry. Grafts sutured to carotid arteries were cultured for two 
weeks before interrogation of early intimal hyperplasia markers. Changes in these markers were 
correlated to differences in wall shear stress predicted by a computational model of fluid flow 
changes based on dilation differences in compliance mismatch. With this relationship 
understanding, we created a high compliance graft that limits development of early markers for 




damage resistant hydrogel formulation that enables safe graft implantation without adversely 
affecting bioactivity of the inner layer. We also identified properties determinant of suture damage 
resistance that enable development of future hydrogel formulations. 
Overall, this work improves multiple aspects of a multilayered graft for long term patency. 
Additionally, we have elucidated fundamental material properties and biological relationships that 
can be used to enhance not only the multilayer vascular graft, but also biomaterial design for other 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Clinical Need and Current Graft Options 
Coronary artery bypass grafting (CABG) surgery is one of the most common procedures 
performed in the U.S. with over 427,000 surgeries performed each year.1 Autologous vessels 
typically harvested from the saphenous vein are the clinical gold standard. However, these vessels 
are unavailable in up to 85,000 patients each year due to previous grafting procedures, systemic 
vascular disease, or a size mismatch between the graft and the artery to be grafted.2-4 
Many approaches have been taken to address the limitations of current clinically available 
grafts. These approaches include cadaver grafts, tissue engineered constructs, and synthetic grafts, 
each with their own advantages as well as drawbacks. Cadaveric grafts are readily available as an 
autograft alternative, but CABG procedures with these grafts have been met with limited success. 
Cadaveric grafts include both human and animal vessels, and all must be heavily processed in 
order to eliminate immunogenic concerns.  In one such process, cryopreservation is utilized to 
reduce antigenicity concerns with little success. This process contributes to creating a more brittle 
graft that can cause early rupture of the grafts.5,6 Even with the use of immunosuppresants, these 
grafts have high failure rates.7,8 Decellularized grafts reduce immunological concerns, but require 
pre-endothelialization for long term success.9,10 
 Tissue engineered grafts have demonstrated increasing success in longer term studies. 
These grafts are typically protein based, such as those made from collagen, elastin, or fibrin.11-15 
The most successful grafts to date are in vitro cultured vascular grafts.16-18 Notably, Niklason et 




polyglycolic acid (PGA) scaffold. ECs are then seeded onto the scaffold after 8 weeks of culture. 
These grafts exhibit high burst pressure, but have proven difficult to translate to human cells, 
requiring additional cellular modifications.19 Although initial data for these grafts is promising, 
the extensive preparation time is not conducive to clinical translation. 
 Synthetic grafts are easily stored and require little to no preparation before implantation. 
Synthetic vascular grafts composed of expanded polytetrafluoroethylene (e.g. Gore-tex®) or 
polyethylene terephthalate (e.g. Dacron®) have demonstrated satisfactory long-term outcomes in 
large- (>8 mm) and medium-diameter (6 - 8 mm) arteries, but poor patency limits their application 
in small-diameter vessels (< 6mm) and has been attributed to thrombosis and the development of 
intimal hyperplasia.20 In order to reduce the thrombogenicity of synthetic grafts, various coatings 
have been introduced to the surfaces of the grafts.21,22 Drug coatings such as Persantin or heparin 
have been investigated. Although the short term results are promising, there is little long-term data 
to establish this as an effective strategy to reduce thrombogenicity.23 Another promising short term 
approach is incorporating nitric oxide (NO) into the graft, which inhibits platelet aggregation.24-26 
Most delivery methods for NO are limited to relatively short time frames, restricted by the amount 
of NO producer that can be incorporated into a graft material.  
In summary, the limited availability of autografts and the low patency rates of synthetic 
grafts, typically lasting no more than 5-10 years, has established a strong clinical need for new 
small-diameter graft design.27 As mentioned above, synthetic grafts typically fail either due to 
thrombosis or reocclusion due to intimal hyperplasia. Improvements to the vascular graft design 
would require an effective thromboresistance strategy that does not necessitate additional 





1.2 Hemostatic Regulation 
1.2.1 Importance of hemostatic regulation 
A critical limitation of synthetic vascular grafts and other early blood-contacting medical 
devices was their propensity to fail due to thrombosis. Aggregation of activated platelets can 
occlude blood vessels and lead to downstream morbidity due to emboli that travel to the patient’s 
lungs or brain. These early failures led to a critical investigation of methods to prevent thrombosis, 
namely the generation of anti-thrombotic coatings for medical devices. Current research aims to 
understand and recapitulate the body’s anti-thrombotic surfaces to improve the patency of blood-
contacting medical devices. The endothelium provides dynamic hemostatic regulation of all blood-
contacting surfaces in the body. Thus, promoting endothelialization of cardiovascular devices is a 
popular strategy for generating long-term thromboresistance and controlling hemostasis without 
the need for systemic anti-platelet therapies. Endothelial cells prevent platelet activation, provide 
a protective and selective barrier to underlying tissues, respond to injury, and activate clotting 
when necessary.10,28-30 Importantly, the endothelial cell layer is a dynamic system that 
accomplishes all of these tasks by responding to cues not only from circulating blood but also from 
the underlying extracellular matrix (ECM).31 These environmental cues, such as biochemicals, 
shear stress, and attachment matrix constituents, are responsible for changes in endothelial cell 
phenotype and determine which anti- or pro-thrombotic constituents are released from the cells 
into the blood stream to regulate hemostasis.32-46,47 Fundamental understanding of how the ECM  
influences endothelial cell hemostatic regulation would enable enhanced cellular interactions with 
small diameter vascular grafts by providing specific targets for cell adhesion, allowing for 





1.2.2 Endothelial cell hemostatic regulation 
Endothelial cells have several mechanisms for regulating coagulation and 
inflammation.48,49 In addition to providing a physical barrier to the pro-thrombotic ECM, 
endothelial cells are responsible for the initiation or direct regulation of coagulation, platelet 
function, and fibrinolysis to minimize adverse consequences of vascular injury, as well as 
maximize vascular repair capabilities.29,50,51 Disruption of these regulatory functions can lead to 
cardiovascular disease or sudden cardiac death, highlighting the importance of the endothelial 
layer in cardiovascular systems.28-30,52-60 
In controlling coagulation, the endothelial cells bind antithrombin III that is responsible for 
inactivation of thrombin, Factor Xa, and Factor IXa in the coagulation pathway, slowing 
coagulation.29 The ECs also express thrombomodulin, which in turn promotes the activation of 
protein C in concert with endothelial protein C receptor.61 Protein C is an anticoagulant that limits 
the conversion of Factor VIII to Factor VIIIa and prevents the conversion of Factor V to Factor 
Va.61 Endothelial cells also prevent coagulation by expressing tissue factor pathway inhibitor 
(TFPI) which inhibits the conversion of Factor VII to Factor VIIa.62 Without these controls, the 
coagulation pathway would proceed unchecked and clotting would be prolific in the body leading 
to increased rates of stroke, embolisms, and heart attacks.28,29  
Platelets play a critical role in coagulation with fibrin-stabilized platelet aggregates able to 
rapidly form hemostatic plugs upon vessel damage.63 Endothelial cells can rapidly promote platelet 
adhesion and activation by producing and releasing von Willebrand factor (vWF). vWF is a blood 
glycoprotein that binds to Factor VIII as a stabilizing agent against protein C, platelet surface 
glycoproteins, and constituents of the ECM. vWF exists in two compartments in endothelial cells: 




subendothelial matrix, and residing in a granular store containing very highly multimerized vWF 
that can be mobilized rapidly in response to agonists such as thrombin.64 Endothelial cells also 
produce ADAMTS13, which cleaves the ultra-long vWF strings (ULVWF) that form to capture 
platelets.43,65-68 Platelets also reduce platelet activation by producing prostaglandin I2 (PGI2) and 
endothelial nitric oxide synthase (eNOS).69 Synthesis of these molecules is triggered by increases 
of intracellular calcium ion concentrations in endothelial cells. PGI2 and nitric oxide (NO) are both 
potent vasodilators and inhibit platelet activation. The powerful anti-aggregatory and vasodilator 
properties of PGI2 and nitric oxide make them critical regulators of hemostasis.  
Endothelial cells also play an important role in fibrinolysis, or the enzymatic breakdown 
of blood clots, an important consideration for medical devices by enabling endothelial cells to help 
eliminate small clots and prevent large thrombi formation. To this end, endothelial cells synthesize 
and acutely release tissue plasminogen activator (t-PA), a protein that is involved in the dissolution 
of blood clots by converting plasminogen to active plasmin. tPA is constitutively released from 
small granular stores that are separate from vWF stores.70 Endothelial cells release plasminogen 
activator inhibitor PAI-1 (the main t-PA inhibitor) in activated conditions to prevent excessive 
fibrinolysis by blocking the action of t-PA.70 The regulation of t-PA and PAI-1 is vital to healthy 
vasculature because an imbalance of either of these factors leads to hemorrhagic disease or 
hypercoagulable states. 
Endothelial cells are responsible for releasing a number of products that trigger signaling 
cascades that carefully balance the cell response to maintain hemostasis. A summary of the 
prothrombotic and antithrombotic agents regulated by endothelial cells is provided in Table 1.1. 




this balance is perturbed. Therefore, it is critical to maintain endothelial cell health when 
attempting to recapitulate the endothelial cell environment for cardiovascular applications.  
 
Table 1.1:  Common hemostatic regulators synthesized by endothelial cells in response to 
environmental cues. 
 Protein Function 
Prothrombotic 
Proteins 
Von Willebrand Factor (VWF) 
Binds platelets to form platelet 
thrombi when in ultra-large 
multimer form [da Silva 2016] 
Tissue Factor (TF) 
Surface protein expressed by 
activated endothelial cells to initiate 
coagulation cascade [White 2010] 
Plasminogen activator inhibitor 
(PAI-1) 
tPA inhibitor [Booyse 1999] 
Antithrombotic 
Proteins  
A disintegrin and 
metalloproteinase with a 
thrombospondin type I motif, 
member 10 (ADAMTS-13) 
VWF cleaving enzyme [Shim 2008] 
Tissue factor pathway inhibitor 
(TFPI) 
Major inhibitor of TF, Factor Xa, 
and thrombin [White 2010] 
Tissue plasminogen activator 
(tPA) 
Regulator of fibrinolysis [Booyse 
1999] 
Endothelial nitric oxide 
synthase (eNOS) 
Synthesizer of nitric oxide that 




1.2.3.3 Basal lamina 
The basal lamina is crucial for the maintenance of a confluent and functional endothelial 
cell monolayer that provides the dynamic hemostatic regulation described above.55,56,71 It is 




selectively filtering molecules that are transported across it.28,72 The basal lamina is composed of 
many components that work synergistically together to not only promote cell adhesion but also 
influence cell phenotype and genotype.73-75 It is composed of collagen, fibronectin, elastin, 
laminin, glycosaminoglycans, and proteoglycans in varying concentrations depending on the 
location of the tissue in the cardiovascular system.30,76,77 Varying these components can change 
the cell response based on ligand type and availability.78 Although it is the combined presentation 
of the individual components that drives cellular functions, understanding how each component 
contributes to the mechanical and biochemical characteristics of the basal lamina will allow for 
improved constituent selection when creating substrates for endothelial cell growth, whether for 
antithrombotic coatings or for investigating cell behavior. A summary of the key components of 





















Role Compositional Variation with Location 
Collagen 
Tensile strength, cell 
adhesion and signaling
Coarse in aortic smooth muscle cell-derived 
substratum; exclusive production of type IV in 
HUVECs; prevalence in I, III, small amounts of 
IV in large blood vessels; large amounts of I and 
III in capillaries; I and III found in smooth 
muscle matrix; abundant in arterial walls; 
present in tunica media; high relative content in 







Exists within ECM of submucosal structures and 
basement membrane structures; prominent in 
migratory pathways for embryonic cells; present 
in loose connective tissue and in clots in 








Major component of basement membranes, 
including cardiovascular basal lamina and tumor 
tissue. 
Elastin 
Tissue recoil and 
elasticity 
Loose layer of fibrils in aortic smooth muscle 
cell-derived substratum; abundant in arterial 










 Collagen is the most prominent constituent of the basal lamina and is responsible for 
tensile strength and cellular adhesion. Although 28 types of collagen have been identified, collagen 
type I and IV are the most prevalent types found in the cardiovascular system.79 Collagens have a 




ECM that impart strength and structure to the basement membrane.76 Collagen’s rope-like 
structure provides resistance to tensile forces by carrying stress.80  Furthermore, collagen is one of 
the main ECM components responsible for imparting cellular adhesive properties through several 
receptors including binding sites for  the α1β1, α2β1, α10β1, and α11β1 integrins, known as the 
collagen receptor subfamily of integrins.81 Attachment to these integrins is promoted via the 
GFOGER peptide sequence.79 In addition to binding via integrins, cells also bind to collagen 
through syndecan-1.82 Therefore, collagen is vital to basal lamina due to providing significant 
mechanical strength and biochemical cues that enable cell adhesion and migration.  
  Fibronectin, a glycoprotein, is another major constituent of the basal lamina and is formed 
by two nearly identical polypeptide chains attached via disulfide bonds to form a dimer structure.83 
Fibronectin exists in both soluble and insoluble forms.83 Soluble fibronectin circulates in the blood 
and other body fluids, and insoluble fibronectin is found within the ECM. Although transcribed 
from a single gene, fibronectin within the ECM has multiple forms as a result of alternative splicing 
that can generate up to 20 variants.83 These fibronectin variants promote specific cellular and ECM 
interactions by generating different adhesive ligands. For instance, fibronectin facilitates cellular 
attachment of endothelial cells to the ECM via integrin binding sites, primarily integrin α5β1, but 
also αvβ3, α4β1, α4β7, and α9β1 with RGD, PHSRN, LDV, and REDV binding sites.83 
Additionally, fibronectin not only binds to cells but also promotes adhesion to other ECM 
components such as collagen, primarily in denatured regions of collagen triple helices through 
functional and structural domains, as well as heparin and fibrin through specific binding 





Elastin is another major component of the basal lamina and provides elastic recovery after 
stretch or deformation of the tissue, a common occurrence in the body’s vasculature. Elastin is 
made from the soluble precursor molecule tropoelastin that generate a highly insoluble crosslinked 
network.80 The lysine amino acids of tropoelastin are extensively crosslinked immediately after 
release from the cell by oxidative deamination of the lysine side chains via the enzyme lysil oxidase 
with subsequent condensation linking two, three, or four side chains.80 The elasticity of the 
resulting elastin network is attributed to the loose, random coil conformation of the resulting 
polypeptide chain. The stretching of elastin is limited by interwoven stiff collagen fibers, and the 
overall stress response of ECM is dictated by the interplay and concentrations of collagen to 
elastin. Elastin has not shown cell adhesive properties and the function appears to be limited to 
providing important mechanical recoil to tissues.80 
Laminin is a key organizer of the basal lamina’s structure as it can self-assemble into 
sheets, bringing together the other basal lamina components through crosslinking. Laminin is 
composed of three long polypeptide chains (an α, a β, and a γ chain) held together by disulfide 
bonds. 18 laminin trimers have been investigated and described, with laminin-1 as the most 
prominent in the basal lamina.  In addition to being an important ECM crosslinker, laminin enables 
ECM interactions with many different cell types through its diverse binding sites for cellular 
surface receptors. For example, laminin has binding sites for integrins α3β1, α6β1, α7β1, and α6β4 
as well as binding sites for syndecans 1, 2, and 4, creating a diverse array of cellular responses and 
interactions.84 
Glycosaminoglycans (GAGs) are unbranched polysaccharide chains composed of 
repeating disaccharide units and are essential to the formation of the ECM as hydrophilic space-




hydrating and filling most of the extracellular space.80 GAGs are considered the “most anionic 
molecules produced by animal cells” and hydrate the ECM by attracting water molecules due to 
their high negative charge.80 GAG chains can be covalently linked to a core protein, forming a 
proteoglycan.  
Proteoglycans are abundant in the ECM and can regulate the activities of secreted ECM 
proteins by binding to them. They play a major role in chemical signaling between cells by 
changing conformations or blocking of binding sites.80 Although many proteoglycans are secreted, 
some remain as trans-membrane proteins, known as syndecans, and act as receptors for ECM 
proteins.85 The diverse family of GAGs and proteoglycans are responsible for not only hydration 
but also ECM-endothelial cell interactions that regulate cellular behavior.  
In summary, the individual components of the ECM work in concert to define the 
biochemical and mechanical landscape of the basal lamina. Interactions of endothelial cells with 
these individual components then initiate signaling cascades to affect cytoskeletal organization 
and gene expression. Understanding the individual qualities and combined synergistic effects of 
the basal lamina constituents allows for tailoring of substrates for desired cell growth and behavior.  
 
1.2.3 Effect of ECM components on endothelial cell hemostatic regulation 
As discussed above, the basal lamina is the ECM that supports endothelial cells in the 
cardiovascular system with major components consisting of collagen, laminin, fibronectin, elastin, 
proteoglycans, and glycosaminoglycans.71,76,77 Endothelial cells bind uniquely to these 
components using different transmembrane proteins, such as integrins and syndecans.55,71 Integrin 
and syndecan binding to ligands on the basal lamina initiates intracellular signaling cascades that 




regulation.28,53,71,86-89,90 Elucidating key relationships between integrin binding, signaling 
cascades, and the corollary changes in a cellular hemostatic regulators has become an area of 
interest for researchers. Elucidation of the key mediators of anti-thrombotic cell behavior can 
provide improved material design of thromboresistant coatings for blood-contacting devices.  
Integrins and syndecans are transmembrane receptors that facilitate ECM-endothelial cell 
adhesion. These transmembrane proteins uniquely interact with ECM ligands and provide a 
method for signal transduction from the exterior of the cell to the interior. Understanding which 
integrins and syndecans are responsible for attachment to individual ECM components in the basal 













1.2.3.1 Integrin Expression in Endothelial Cells  
Integrins are critical for not only anchoring cells to the ECM and mediating migration but 
also important transducers of intracellular signaling that influence cell phenotype.91,92 Integrins are 
a large family of transmembrane proteins that exist as heterodimers, with 18 unique α and β 
subunits that combine to form 24 distinct dimers that bind to specific amino acid sequences within 
ECM proteins.71 A list of common integrins and their respective ligands are listed in Table 1.3.  
Endothelial cells express α1β1 that binds to collagen, α2β1 that binds to collagen and laminin, 
α3β1, α6β1, and α6β4 that bind to laminin, α4β1 and α5β1 that find to fibronectin, and αvβ3 and 
αvβ5 that selectively bind to vitronectin.87,93,94 The extracellular portion of these transmembrane 
proteins links to ligands on the ECM, and the intracellular part of integrins associate with actin 
binding proteins, including vinculin, α-actinin, paxillin, talin, zyxin, tensin, and filamin.95 
Signaling pathways are then activated by the actin binding proteins which may lead to downstream 
changes in the chemical or mechanical composition of the ECM, or affect cell behavior such as 
proliferation, migration, and differentiation.96,97 One of the key regulators of integrin-matrix 
signaling includes the focal adhesion kinase, or FAK, and can play a role in inflammation and 
hemostasis.98 For example, one of the major signaling pathways initiated by the Src-FAK complex 









Table 1.3:  Summary of relevant integrins with corresponding cell expression and extracellular 
ligands. Fg= fibrinogen, Coll=collagen, Fn= fibronectin, Vn= vitronectin, Tn= tenascin, Ln= 
laminin, Opn= osteopontin, Tsp= thrombospondin. 
Integrin Cell type 
Proteins with attachment 
ligands 
α1β1 Endothelial cells, lymphatic endothelial cells Coll VI, Col lI, Ln 
α2β1 Human platelets, lymphatic endothelial cells Coll 1, Coll IV, Ln 
α5β1 HUVECs Fn, Fibrillin-1 
αIIbβ33 human platelets  
αvβ6 epithelial cells 
Fn, Fg, Vn, Tn, LAP-TGFβ, 
Fibrillin-1 
αvβ1 SMCs, fibroblasts, endothelial cells Ln, Fn, Opn, Vn 
αvβ3 
Human platelets, endothelial cells, SMCs, 
fibroblasts, leukocytes 
Fg, Vn, Tn, Opn, Tsp, Fn, 
VEFG-A, Fibrillin-1, vWF 
α4β1 Endothelial cells, leukocytes Fn 
α9β1 Endothelial cells 
Tn, VCAM-1, VEFG-A, 
VEGF-C, VEGF-D, HGF 
α6β4 Endothelial cells Ln 
αIIbβ3 Human platelets Fg, Fn, vWF 
αEβ7 Leukocytes E-cadherin 
αXβ2 Leukocytes Fg, heparin 
α6β1 endothelial cells Ln 
α8β1 SMCs Fn, LAP-TGFβ 
αvβ5 
Endothelial cells, SMCs, platelets, epithelial 
cells, leukocytes 
Opn, Fg, Vn, Fn, Tsp 
 
 
Not only does the type of integrin affect cell adhesion and signaling, but the location of the 
integrins and their abundance affect the strength of cellular adhesions and response of the cell. For 
example, focal adhesion complexes are strong, stable adhesions formed when integrins are 
clustered on the cell surface, allowing for many cytoskeletal filaments to attach at the resulting 
plaque.99 Endothelial cells are dependent on these attachments for cell survival, as detachment 
from their substrate leads to upregulation of apoptotic signaling. Focal adhesion complexes also 




that plays an important role in cell survival by activating essential signaling pathways critical for 
the prevention of apoptosis.12,71,100-102 
There are a multitude of other focal adhesion proteins involved in establishing and 
maintaining cytoskeletal linkages: integrin-bound proteins that directly bind actin, such as talin, 
α-actinin, and filamin; integrin-bound proteins that indirectly associate with and regulate the 
cytoskeleton such as kindling, integrin-linked kinase (ILK), paxillin, and FAK; non-integrin-
bound actin-binding proteins, such as vinculin; and adaptor and signaling molecules that regulate 
the interactions of the proteins of the afore-mentioned groups.95 These molecules then go on to 
affect many common cellular pathways such as the Akt, ERK, JNK, RhoA, Rac1, and Cdc42 
pathways. Each of these pathways then uniquely affects cell survival, proliferation, differentiation, 
migration, adhesion, and polarity by modulating gene expression, cell cycle regulation, focal 
adhesion turnover, and actin dynamics. A review by Legate et al. provides detailed information 
about the individual pathways and their effects.95 For example, β1 integrins are involved in a 
signaling pathway with RACK that results in increased cell migration toward insulin-like growth 
factor 1, or IGF-1.  Binding of the αvβ3 integrin has been shown to induce a β3-SHP-2 interaction 
that sequesters phosphatase and prolongs IGF1R signaling, that plays an important role in growth 
and development.86,95,103,104  
Overall, integrins provide complex and wide-ranging modes of attachment and signaling 
in endothelial cells. The endothelial cell presentation and available ECM binding sites dictate the 
resulting cell behavior. However, it remains challenging to isolate the role of one integrin from 
another in order to discern the individual and synergistic contributions of these interactions. 
Elucidation of these roles would provide greater understanding of how cells regulate hemostasis 




1.2.3.2 Syndecans  
The evolving roles of syndecans, type I membrane glycoproteins composed of GAG chains 
covalently linked to a core protein, is becoming increasingly important in understanding ECM -
endothelial cell interactions.105 Syndecans often act as co-receptors to ligands such as vascular 
endothelial growth factor (VEGF) and fibronectin that have interactions of particular interest in 
the ECM and are relevant for tissue engineering.106 The syndecan family is organized into four 
group members: syndecans-1, -2, -3, and -4, each with distinct functions as shown in Table 1.4. 
For example, syndecan-1 regulates cell-interstitial collagen adhesion and binds to fibronectin, as 
well as growth factors via heparin sulfate chains.85 Syndecan-1 is down regulated in endothelial 
cells and can promote differentiation in vascular smooth muscle cells.107,108 Syndecan-2 is also 
found in endothelial cells and binds to ECM components such as fibronectin and growth 
factors.85,109 However, further research is required to understand the specific roles of syndecan-2 
in cell adhesion. Syndecan-3 is predominantly found in muscle cells and neuroblastoma cells 
within the nervous system and binds to certain growth factors.85 However, it has low affinity for 
fibronectin, collagen I, III, and laminin and therefore plays a limited role in cell adhesion to ECM.85 
Therefore, syndecan-3 is of limited interest in hemostatic regulation. Syndecan-4 is found to be 
ubiquitously expressed in all cell types, making it a more widespread component than the other 
syndecans and is known to be involved in focal cell adhesion, a tight interaction between the cell 
and ECM, ensuring intracellular signaling.89 Syndecans influence cell interactions significantly in 
their roles in cell adhesion and binding to ligands in the ECM. Although the importance of 





Table 1.4: Summary of the syndecan family and their roles as cell attachment mediators. 
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1.2.3.4 Effect of each ECM component 
In an effort to recapitulate the basal lamina, many ECM-mimetic platforms have been used 
to culture and examine the behavior of endothelial cells.111,112 As discussed earlier, endothelial 
cells bind to ECM proteins via integrins and syndecans, which then initiates intracellular signaling 
that modulates cell behavior. Although many of the intricacies of the cell-ECM binding are not 
explicitly discussed in many of the studies discussed here, comparisons of behavior between 
various ECM components can be used to identify roles of different integrin or syndecan binding 
and corollary effects on hemostatic regulation. 
Collagen-initiated Hemostatic Regulation  
Collagen is one of the most prevalent adhesive proteins found in the body and is a 




studies are typically performed using mammalian-derived collagen either as a coating or as a 
crosslinked gel.113 Endothelial cell adhesion to collagen is mediated by integrins α1β1, α2β1, 
α10β1, and α11β1 as well as syndecans 1 and 4.93 Studies have also been performed on collagen 
mimics that have more tailored integrin interactions.114 These typically require coating studies or 
chemical crosslinking into another network, as they do not form networks on their own.115 
Collagen coat studies have demonstrated a difference in not only cell behaviors such as 
migration and proliferation as compared to TCPS but also differences in hemostatic regulation.116-
120 For example, endothelial cells cultured on collagen-coated ePTFE demonstrated lower levels 
of PGI2 and tPA as compared to endothelial cells on an un-coated ePTFE control.16 This would 
indicated a less thromboresistant phenotype, but this study did not analyze the production of 
complementary pro-thrombotic factors in the endothelial cells cultured on these substrates.16 
Another collagen coat study noted an increase in NO production with endothelial cells on the 
collagen coat as compared to endothelial cells on TCPS, indicating a more thromboresistant 
phenotype.116 However, like the previous study, the authors did not discuss the production of pro-
thrombotic factors and how the substrate difference would affect their expression. Studies on 
collagen gels have shown that endothelial cells have decreased expression of PGI2 and vWF, 
indicating the signaling from collagen attachment is important for endothelial cell regulation of 
hemostasis.120 
Scl2 Proteins 
Studies on collagen mimics that allow for more specific integrin binding are utilized to 
further elucidate the interactions between endothelial cells and collagen. Scl2 proteins provide the 
unique opportunity to tune bioactivity to target specific integrin binding. Streptococcal collagen-




but do not require post-translational modification for helix formation.121 The Scl2 proteins, 
however, are devoid of the native binding sites associated with collagen.121 Therefore, the 
bioactivity of the Scl2 protein can then be customized by site-directed mutagenesis to introduce 
peptide sequences for specific cell surface receptor targeting.122 For example, the collagen-derived 
peptide binding sequence GFPGER targets the integrins α1β1 and α2β1 and has been incorporated 
into Scl2 to tailor bioactivity.122,123 Scl2 proteins with this targeting sequence are known as 
Scl2GFPGER proteins, and the binding of integrins to this peptide sequence is strengthened by the 
triple helical structure of the Scl2GFPGER protein.124 Scl2GFPGER proteins have been demonstrated to 
not promote platelet aggregation while still promoting endothelial cell adhesion and 
migration.54,86,125,126 Endothelial cells showed increased adhesion on poly(ethylene glycol) (PEG) 
hydrogels containing the Scl2GFPGER proteins compared to PEG gels alone, as well as comparable 
adhesion to PEG hydrogels containing collagen.54,126 Endothelial cells seeded on these scaffolds 
demonstrated a decrease in NOS3 and TM gene expression, and e-selectin gene expression 
increased compared to collagen gels. This suggests that integrins α1β1 and α2β1 binding are 
responsible for these gene expression changes.119  
Based on the evidence in the studies described above and shown in Table 1.5, the binding 
of these integrins and syndecans to collagen are responsible for the observed changes in the 
endothelial cell expression of hemostatic regulators. These integrins could be used as targets to 
increase the thromboresistance such as through increased NO production. However, parsing out 
the specific integrin interactions is needed to identify specific integrin binding targets for tissue 






Table 1.5: Summary of the effects of endothelial cell attachment to collagen on hemostatic 





















Increase in NOS3 
compared to TCPS; No 
significant change in  













Decrease in PGI2 and 
vWF secretion; No 
difference in basal levels 
of PGI2, tPA increase 
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tPA; no difference in tPA 
secretion; PAI increased; 
Different levels of PGI2, 



















Decrease in NOS3 and 
TM on PEG-Scl2 and E-
selectin increased 
compared to collagen; no 







Fibronectin and Gelatin-initiated Hemostatic Regulation 
Endothelial cells bind to fibronectin via integrin α5β1, but also α4β1, α4β7, and α9β1 as 
well as syndecan 4.83 When endothelial cells are seeded on fibronectin coats, a measured increase 
in PGI2 as well as tPA was observed as compared to uncoated ePTFE and TCPS.16,117,118 
Endothelial cells bind to gelatin also through integrin α5β1 as well as αvβ3, binding specifically 
to the RGD binding sequence that becomes accessible on denaturation of the collagen triple 




compared to the unmodified ePTFE, suggesting a more thromboresistant phenotype.129 Studies are 
commonly performed using RGD, as it is a readily available peptide sequence. When endothelial 
cells are cultured on RGD that is incorporated into hydrogels, ADAMTS-13, TFPI, tPA, vWF, TF, 
P-selectin all increased compared to TCPS.106 With these increases and results summarized in 
Table 1.6, endothelial cells appear to be much more activated on RGD peptides that attach to the 
integrins α5β1 and αvβ3. Again, these changes highlight specific integrin and syndecan targeting 




































Table 1.6: Summary of the effects of endothelial cell attachment to fibronectin and gelatin on 
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Increase in PGI2 
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compared to bare 
ePTFE; no 
significant 











Laminin-initiated Hemostatic Regulation  
Endothelial cells bind to laminin via integrins α3β1, α6β1, α7β1, and α6β4 as well as 
syndecan 2.93 Studies on laminin coats have demonstrated an increase in PGI2 expression, 
indicating a more thromboresistant phenotype of the endothelial cells.130 Studies have also been 
performed on laminin-mimetic hydrogels. A laminin peptide sequence targeting syndecan binding 
was covalently linked to the surface of poly(ethylene glycol) diacrylate hydrogels. Cells grown on 
these constructs were then compared to hydrogels with RGD binding sequences linked to the 
surface of the gels, which interact with integrins α5β1 and αvβ3.106 The endothelial cells grown on 
the laminin-mimetic gels showed ADAMTS-13, TFPI, tPA, vWF, TF, and P-selectin all increased, 
with NO increased compared to plate grown cells.106 The change of gene expression of hemostatic 
regulators in targeting syndecan binding indicates that syndecans also play an important role in 
endothelial cell hemostatic regulation. The effects of laminin on endothelial cell hemostasis are 
shown in Table 1.7. 
 
Table 1.7: Summary of the effects of endothelial cell attachment to laminin on hemostatic 
regulator molecule expression. 
Substrate 
Application 
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tPA, tPA, vWF, TF, P-
selectin all increased; 
NO increased 










The studies discussed here have demonstrated the importance of the substrate on 
endothelial cell hemostatic regulation, but few have investigated specific binding interactions and 
the correlated changes in endothelial cell gene expression and thromboresistance.  Future 
investigation would need to isolate integrin interactions on well controlled surfaces for the culture 
of endothelia cells. Using these platforms it would then be possible to analyze the changes in gene 
expression as well as the functional changes in endothelial cell hemostatic regulation. Once 
specific interactions have been correlated to changes in hemostatic regulation, mechanisms and 
signaling pathways can be elucidated. Understanding signaling pathways and mechanisms could 
lead to further tailoring of coating designs for endothelialization of biomedical devices. By 
elucidating the specific effects of integrin attachment on hemostatic regulation, it would then be 
possible to target specific endothelial cell binding mechanisms to promote a thromboresistant 
phenotype in an endothelial cell monolayer. 
 
1.3 Biomechanics and Intimal Hyperplasia 
1.3.1 Intimal hyperplasia 
Intimal hyperplasia is characterized by intimal thickening that eventually causes vessel re-
occlusion and typically occurs at the distal anastamosis of a grafted vessel.27,131-133 This intimal 
thickening occurs due to many cell phenotype changes and ECM organizational changes. Central 
to the disease progression are the changes to vascular smooth muscle cells (VSMCs). VSMCs are 
highly specialized cells responsible for the contraction and regulation of blood vessel tone, blood 
pressure, and blood flow.134 In normal adult arteries, differentiated VSMCs present very low 
proliferation rates and exhibit a contractile phenotype expressing proteins such as smooth muscle 




(SM22α), h-caldesmon and calponin, important for the regulation of the vessel contraction.134-136 
However, during the progression of intimal hyperplasia, VSMCs proliferate and abnormally 
migrate towards the innermost layer of the arterial wall promoting an increase of the wall thickness 
and a consequent reduction of blood flow.98,137 When intimal hyperplasia is initiated due to trauma, 
changes in wall shear stress, or inflammation, VSMCs undergo a de-differentiation process 
towards a proliferative phenotype, associated with a higher proteoglycan-rich extracellular 
matrix.133,135,136,138 Proliferative VSMCs present an increased synthetic activity with higher 
expression of hyaluronic acid, collagen type 1, elastin, versican, biglycan and fibronectin 
(interstitial matrix components) while decreasing the synthesis of basement membrane 
components such as laminin.134,136,138 
Although most of the intimal hyperplasia morphological changes are associated with the 
phenotypic switch of VSMCs, all the components of the vessel play an important role in the 
modulation of the disease initiation and progression.133 Vascular endothelial cells are key 
regulators of vessel homeostasis and secrete molecules able to prevent coagulation, promote 
vasodilation, and control VSMCs proliferation and differentiation.133,138 However, in the absence 
of laminar blood flow or injury, endothelial cells become dysfunctional and secret agents that 
promote coagulation, vasoconstriction, switch VSMCs to a proliferative phenotype, and regulate 
the infiltration of inflammatory cells. Dysfunctional endothelial cells express adhesion molecules 
such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-
1), E-selectin, and P-selectin.138 Endothelial cells and infiltrated immune cells also produce 
cytokines and growth factors that act as inflammatory mediators and further stimulate vascular 
remodeling.138,139 




Poor compliance matching has been linked to low patency rates in synthetic grafts. Intimal 
hyperplasia causes failure of approximately 10-30% of synthetic grafts.132 This high rate of failure 
has been correlated with a compliance mismatch between the grafting material and the native 
vasculature.132,140 Despite this strong empirical correlation, the mechanisms by which compliance 
mismatch leads to intimal hyperplasia are relatively poorly understood. It is theorized that the 
compliance mismatch leads to a flow disruption at the distal anastomosis, that then leads to low 
wall shear stress.132,141 The vessel wall, in response to the low wall shear stress, attempts to correct 
the flow disruption with intimal thickening, ultimately leading to re-occlusion of the vessel.140 
It has been difficult to directly relate compliance-mismatch and the resulting changes in fluid 
dynamics to the development of intimal hyperplasia because of confounding factors of graft 
properties. For example, the often cited high-compliance grafts with improved patency are 
autografts as compared to the low-compliance synthetic grafts.140 Isolation of the effect of 
compliance is ideally conducted on synthetic grafts that can vary compliance independent of other 
graft variables. Identification of the cause of intimal hyperplasia would allow for improved small 
diameter vascular graft design. However, in order to design vascular grafts with improved patency, 
the complex cascade of events that begins with changes in the endothelium and initiates the smooth 
muscle cell phenotypic alterations that typify intimal hyperplasia need to be elucidated.   
 
1.4 Multilayer Vascular Graft 
1.4.1 Multilayer graft design 
With the limitations of current efforts toward a small diameter vascular graft in mind, there is 
a clear need for an off-the-shelf, post-implantation endothelialization small diameter vascular graft 




our lab has developed a dual layered vascular graft.86 Addressing both the mechanical and 
bioactivity design requirements is difficult to achieve in a single material. Therefore, we have 
created a layered construct to address the requirements separately. The graft consists of an 
electrospun polyurethane outer layer and a bioactive hydrogel inner layer.  
The electrospun outer layer has been tuned to meet the mechanical demands of a vascular graft. 
Polyurethanes are commonly used in cardiovascular applications as they are typically 
biocompatible, durable, and exhibit strong fatigue resistance.142,143 Electrospinning this material 
creates a fibrous scaffold with mechanical properties that can be easily modulated by tuning the 
electrospinning parameters to alter fiber morphology and mesh thickness. By altering these 
parameters, we are able to impart high compliance, matching that of the saphenous vein, while 
maintaining high burst pressure and suture retention strength. Increasing this compliance further 
would provide a compliance match to the native vasculature. Creating grafts within a range of 
distinct compliances can also be used to investigate the effects of compliance on the development 
of intimal hyperplasia. Modulating compliance is a novel and important tool for understanding 
disease initiation and progression of intimal hyperplasia. 
The inner layer of the vascular graft is designed to impart both initial and sustained 
thromboresistance. The inner layer is made of a poly(ethylene glycol) (PEG) based hydrogel that 
provides initial thromboresistance to the graft. PEG based hydrogels have been widely established 
to be bio-inert and resist protein adhesion.144-147 However, this initial thromboresistance will 
diminish over time. In order to promote sustained thromboresistance, endothelialization of the 
graft is required. To this end, Scl2GFPGER proteins are used to promote endothelial cell adhesion 
and proliferation on the hydrogel layer. Scl2GFPGER proteins, however, cannot self-assemble into 




graft.126 Incorporation of the protein is accomplished by functionalizing the protein with a PEG 
linker that covalently crosslinks into a PEG hydrogel network.126  
To create a multilayered graft composite, the outer layer is first electrospun onto a rotating 
mandrel. The tubular fibrous mesh is then subjected to an ethanol ramp to allow for penetration of 
the aqueous hydrogel precursor solution.  The meshes are placed in a cylindrical mold with an 
inner glass mandrel, and hydrogel solutions are pipetted between the mandrel and the mesh, then 
crosslinked with UV light, as demonstrated in Figure 1.2. This dual layered construct has been 
well characterized previously, displaying no delamination between the layers and long term 




Figure 1.2: Fabrication of the multilayer vascular graft.  
 
 
1.4.2 Limitations of multilayer vascular graft 
The proposed graft has met many of the design requirements set forth that include initial 
thromboresistance and increased compliance. However, the multilayered graft required further 
investigation and improvement in order to be a relevant clinical alternative to the currently 




hemostatic regulation had yet to be elucidated. This crucial understanding is required in order to 
promote endothelial cell adhesion and thromboresistance simultaneously. Although the graft 
matched the compliance of the saphenous vein, this compliance is still lower than that of the carotid 
and coronary arteries to which the graft will be sutured. Presumably, the compliance mismatch 
still allows for the development of intimal hyperplasia. However, the relationship between 
compliance mismatch and intimal hyperplasia has not been definitively defined. Therefore 
elucidation of this relationship was required for identification of graft compliance that limits 
intimal hyperplasia. Finally, additional improvements were required for the inner hydrogel layer 
as particles are dislodged during suturing, creating pseudo-embolisms that create risk for morbidity 
and mortality. This would require creating a suture damage resistant hydrogel formulation. 
The work presented here addresses these limitation and requirements. In Chapter II, we 
elucidate the effect of specific integrin binding on endothelial cell hemostatic regulation to 
optimize hydrogel inner layer cellular interactions for both initial and sustained thromboresistance. 
In Chapter III, we correlate effect of compliance on development of intimal hyperplasia and 
created a high compliance graft to limit the onset of intimal hyperplasia. The model used to 
determine this correlation will also serve has a high-throughput screening method for vascular 
grafts. Finally, in Chapter IV, we identify hydrogel characteristics that predict suture damage 
resistance and created a hydrogel for the multilayer graft inner layer that is suture damage resistant 
and biostable. With these improvements, we aim to increase the long term patency of the synthetic 




CHAPTER II  




Thromboresistance is critical to the success of the small diameter multilayer vascular graft. 
We have previously established initial thromboresistance utilizing a hydrogel-based inner layer. 
In order to promote sustained thromboresistance, the inner layer must also support 
endothelialization.86 As discussed earlier, endothelialization is an effective strategy to impart 
hemostatic regulation to the graft, and we have previously demonstrated the ability to promote 
endothelial cell adhesion and migration while resisting platelet adhesion.86,125 In order to promote 
a thromboresistant endothelial cell layer in the lumen of the multilayer graft, it is critical to 
understand the integrin binding and signaling that encourages an anti-thrombotic phenotype in the 
endothelial cells. Although there are numerous studies focused on promoting a confluent 
endothelial layer, relatively few studies have investigated the downstream effects of the 
intracellular signaling from specific integrin binding.106,115 Previous work has demonstrated a 
general increase in thrombogenicity of endothelial cells grown on gelatin that predominantly attach 
via the integrins α5β1 and αvβ3 in ECs.106 A decrease in thrombogenicity has been observed in 
endothelial cells cultured on collagen that predominantly attach via the integrins α1β1 and α2β1 
in endothelial cells.116,148 However, many of these studies are confounded by multiple integrin 
interactions with individual effects not well isolated.115 Additionally, many studies do not control 
for the number of adhesion sites available for binding between samples.115 Although general trends 




endothelial cell regulation of hemostasis have yet to be elucidated. Therefore, identification of the 
optimal combination of integrin binding events that promotes an anti-thrombotic phenotype in 
endothelial cells will allow for better design of cardiovascular devices. 
In the work presented here, we utilized bioactive hydrogels to elucidate the individual and 
synergistic effects of integrin interactions on the anti-thrombotic phenotype of endothelial cells. 
To target specific HUVEC integrin interactions, we fabricated a series of bioactive hydrogels: 
PEGDA-collagen and PEGDA-Scl2GFPGER to target integrins α1β1 and α2β1, PEGDA-gelatin to 
target integrins α5β1 and αvβ3, and PEGDA-collagen+gelatin to target integrins α1β1, α2β1, α5β1, 
and αvβ3, as shown in Figure 2.1. We then demonstrated that cell attachment to these gels was 
mediated through the targeted integrins using antibody blocking. This enabled the study of the 
effect of integrin-mediated attachment on gene expression of hemostatic regulators. Finally, we 
correlated the gene expression changes induced by specific integrin attachment to changes in 
platelet activation and adhesion. Overall, this study provides key information on the role of 
integrin-interactions in endothelial cell hemostatic regulation that will enable improved 






Figure 2.1: Integrins used in attachment to bioactive PEG-based hydrogels. Different platforms 
target specific integrins to promote attachment and intracellular signaling. Collagen and 
Scl2GFPGER target α1β1 and α2β1; gelatin targets α5β1 and αvβ3; and the combination 
collagen+gelatin targets α1β1, α2β1, α5β1, and αvβ3. 
 
 
2.2 Materials and Methods 
2.2.1 Cell culture 
Human umbilical vein endothelial cells (HUVECs) at P0 were purchased from Lonza. Cells 
were seeded in a tissue culture treated T-75 flask with EGM-2 endothelial cell growth medium 
(Lonza) and allowed to grow to confluence. Cells were used between passages 2 and 8 for the 
following studies.  
2.2.2 Integrin expression analysis by flow cytometry 
Cell expression of integrins was determined by conjugated antibody staining of cells in 
suspension. HUVECs between passages 2 and 5 were cultured in tissue-culture treated 
poly(styrene) T-75 flasks to 90% confluency. HUVECs were released from the flasks using TryplE 
Express (ThermoFisher Scientific) 1:10 in sterile PBS. Cells were then spun down and 




106 cells. Cells were then stained with fixable viability dye 450 (BD Biosciences) for 20 minutes 
on ice. Samples were then washed with 3mL flow buffer, spun down, and resuspended in flow 
buffer. Cells were then incubated with the respective integrin or syndecan antibody (anti-α1 and 
anti-α2 at 5μl/mL; anti-αV and anti-α5 at 2.5μl/mL) on ice for 30 minutes. Cells were again washed 
with flow buffer, spun down, then resuspended in 400μL 4% paraformaldehyde to fix the cells. 
Surface expression was then analyzed using the BD LSR II Flow Cytometer. Relative fluorescence 
was used to compare levels of expression. 
2.2.3 PEGDA synthesis 
Polyethylene glycol diacrylate (PEGDA) was synthesized according to a method adapted 
from Hahn, et al.149 Briefly, acryloyl chloride (4 molar equivalents) was added dropwise to a 
solution of PEG diol (3.4 kDa; 1 molar equivalent) and triethylamine (TEA, 2 molar equivalents) 
in anhydrous dichloromethane (DCM) under nitrogen. The reaction was stirred for 24 hours, and 
then washed with 2M potassium bicarbonate (8 molar equivalents). After drying with anhydrous 
sodium sulfate, the product was precipitated in cold diethyl ether, vacuum filtered, and dried under 
vacuum. 
2.2.4 Bioactive hydrogel fabrication 
 Bioactive hydrogels were fabricated by conjugating Scl2GFPGER, collagen, and/or gelatin 
into polyethylene glycol diacrylate (PEGDA) gels using a photopolymerizable linker. Collagen 
(rat tail type I, Sigma) and gelatin (Type B, Sigma) were received as lyophilized powders and used 
as received. Scl2GFPGER is a recombinant protein based on the streptococcal collagen-like protein 
2 (Scl2) that has been modified by site-directed mutagenesis to include the peptide sequence 
GFPGER that interacts with α1 and/or α2 integrin subunits. Scl2GFPGER was expressed using E. 




removed with pepsin cleavage in acid at a pH of 4. The protein was then dialyzed to water, frozen 
at -80˚C overnight, and lyophilized. Scl2GFPGER, collagen, and gelatin were functionalized 
separately with an acrylate-PEG3400-NHS linker (JenKem) at a ratio of 10% of the protein’s 
lysines. Functionalized collagen and Scl2GFPGER were dissolved at 4 mg/mL in 20 mM acetic 
acid, functionalized gelatin was dissolved at 4 mg/mL in water, and a 1:1 ratio of functionalized 
gelatin and collagen were dissolved at 4 mg/mL in acetic acid.  PEG(3.4k)DA was added to each 
solution at 10wt% and Irgacure 2959 solution (0.01mg per 100μL 70% ethanol) was added at 1% 
of the polymer. Solutions were crosslinked between two glass plates on a UV plate for 6 minutes 
on each side to a thickness of 0.75 mm. The resulting bioactive hydrogels (PEG-Col, PEG-Gel, 
PEG-Col/Gel, PEG-Scl2GFPGER) and the control (PEG) were swelled overnight in sterile PBS 
and two additional PBS changes were performed before subsequent use in cell culture experiments. 
2.2.5 Antibody blocking of integrins 
Cells were cultured as described above and resuspended at 33,000 cells/mL in EGM-2 
supplemented with bullet kit (Lonza). Cells were then divided into their respective sample tubes 
with 10,000 cells in 300 μL per sterile 0.5 mL tube. Cells were then incubated with their respective 
integrin or syndecan antibody at room temperature for 15 minutes (Anti-integrin α1 (BioLegend) 
was used at a concentration of 1.33μg/105 cells; anti-integrin α2 (BioLegend) was used at a 
concentration of 0.665μg/105 cells; anti-integrin αV (BioLegend) was used at a concentration of 
0.25μg/105 cells; anti-integrin α5 (Millipore) was used at a concentration of 0.333μg/105 cells; anti-
integrin β1 (Millipore) was used at a concentration of 0.333μg/105 cells ). 100 μL of 
cell/media/antibody solution was then added to the hydrogels in the 96 well plate and incubated 
for 30 minutes at 37°C and 5% CO2. After incubation, gels were washed 2X with sterile PBS to 




and then washed 2X with sterile PBS. Cells were then permeabilized with 0.1% Triton X 100 in 
PBS and stained with rhodamine phalloidin (f-actin/cytoplasm) and SYBR green (DNA/nucleus). 
Representative images were taken and cell counts assessed for each substrate and integrin 
blocking. 
2.2.6 Gene expression analysis 
Cell seeding was performed as described above. Instead of fixing the cells, gels were 
moved to new wells for mRNA extraction using Trizol. Trizol was added to the first of three wells 
of each condition and left for 1 minute to lyse the cells, then pipetted up and down for mixing. The 
500μL of Trizol was then moved to the subsequent wells, repeating the lysing steps for each 
condition. 100μL of chloroform was added to each tube of Trizol and shaken vigorously by hand 
for 15 seconds. Samples were then incubated for 3 minutes at room temperature, then centrifuged 
at 12,000 x g for 15 minutes at 4°C. The mRNA-containing aqueous phase was removed and placed 
in a new tube. 0.5mL of 100% isopropanol was added to the aqueous phase and incubated at room 
temperature for 10 minutes. The solution was then centrifuged at 12,000 x g for 10 min at 4°C. 
The RNA pellet was washed with 0.5ml of 75% ethanol and vortexed. The solution was again 
centrifuged at 7,500 x g for 5 minutes at 4°C and the wash discarded. The isolated RNA was 
resuspended in RNase-free water. Forward and reverse primers for qRT-PCR were acquired from 
Integrated DNA Technologies for the following hemostatic regulators in HUVECs: TF, TFPI, 
ADAMTS-13, vWF, tPA, eNOS, and the housekeeping gene GAPDH (Table 2.1). mRNA was 
converted to cDNA utilizing the SuperScriptIII kit and manual (Invitrogen). Briefly, 1μL of 
primer, 1μL of dNTP mix, up to 5μg total RNA, and DEPC-treated water to 10μL were mixed and 
incubated at 65°C for 5 min, then placed on ice for 1 min. cDNA Synthesis Mix was made by 




SuperScript® III RT. 10uL of cDNA Synthesis Mix was added to each RNA mixture, gently 
mixed, and incubated for 10 min at 25°C followed by 50 min at 50°C. The reactions were 
terminated at 85°C for 5 min and chilled on ice for 5 min. 1μL of RNase H was added to each tube 
and incubated for 20 min at 37°C. cDNA was then either used immediately for qRT-PCR or stored 
at -20°C. All gene expression is represented as a fold change compared to HUVECs attached to 
TCPS. 
 
Table 2.1: Gene targets and their peptide sequences used for qrt-PCR. 
 Gene Peptide Sequence Forward 
Pro-thrombotic 
vWF GTTCGTCCTGGAAGGATCGG 








2.2.7 Platelet adhesion 
Platelet attachment was used as an initial measure of thromboresistance of the new 
hydrogel formulations. Circular hydrogel specimens were punched from the hydrogel slabs and 
placed in a 48 well plate. Cells were grown to confluence on the protein hydrogels. Platelets were 
isolated from human whole blood drawn from a volunteer and mixed with ACD via inversion. The 
mixture was centrifuged at 990rpm for 15 minutes to isolate the protein rich plasma (PRP) layer. 
The PRP layer was removed and prostacyclin (Sigma Aldrich) was added at 10µL/mL and 
centrifuged again at 1500rpm for 10 min to form a platelet pellet. The pellet was resuspended in 




resuspended in Tyrode’s buffer at half the original volume of PRP. Sudan B Black solution (5% 
in 70% ethanol) was added to the platelet solution at a 1:10 ratio for 30 minutes at room 
temperature. The stained platelets were then washed with PBS 3 times by resuspending the pellet 
in PBS then centrifuging at 1500rpm for 8 min. Platelets were counted and resuspended at a 
concentration of 10 x 106 platelets/mL in sterile PBS. 500µL platelet suspension was added in each 
test well, and platelets were allowed to adhere to substrate for 30 min at 37°C on a shaking 
incubator. Gels were transferred to new wells and washed twice with PBS, then carefully placed 
into microcentrifuge tubes and bound cells were lysed with 150μL DMSO for 15 min at room 
temperature. 150μL of PBS was added to each sample and the solution moved to a cuvette for 
reading on a spectraphotometer (400-650nm, SpectraMax M2, Molecular Devices). 
2.3 Results  
2.3.1 Integrin expression 
In order to determine the relative abundance of integrins presented on the cell surface, the 
relative fluorescence of antibody detection was measured in flow cytometry. The lowest 
fluorescence was observed when staining the integrin subunit α1 (259 ± 54), and complexes most 
commonly with β1 to form α1β1 (Figure 2.2). The highest fluorescence was measured for integrin 
subunit α2 (1163 ± 68), and complexes most commonly with β1 to form α2β1. Both integrin 
subunits α5 and αv exhibited fluorescence at about half of the intensity of α2 (536 ± 48 and 650 ± 
83, respectively). Integrin subunit α5 most commonly complexes with β1 to form α5β1, and 
integrin subunit αv most commonly complexes with β3 to form αvβ3. This data indicates that, of 
those analyzed, the most highly expressed integrin presented on the HUVEC surface is α2β1, with 







Figure 2.2: Relative abundance of major integrins involved in HUVEC attachment to 
extracellular matrix proteins. Relative fluorescence was measured in flow cytometry. Antibodies 
used for staining were administered with the following concentrations: anti-α1 and anti-α2 at 
5μl/mL; anti-αV and anti-α5 at 2.5μl/mL. Data shown is average ± standard deviation. * 
Indicates significance from other groups, p<0.05, as determined by 1-way ANOVA with a post-
hoc Tukey’s test. 
 
 
2.3.2 Antibody integrin blocking 
   Antibodies to these integrins were then selectively blocked to confirm the dominant 
integrin interactions responsible for mediating HUVEC adhesion to each of the bioactive 
hydrogels. When blocking integrin subunits on PEG-Col hydrogels, the largest decrease in 
attachment was observed when blocking α2, with only 27.5% of cells adhered. The combination 
α1+α2 blocking resulted in a further reduction in cell attachment to 16.5% of the control (Figure 
2.3A). No significant decrease in cell attachment was observed with either integrin αv or α1 
blocking. In contrast, the reverse trend was observed with PEG-Gel hydrogels with minimal effect 
on cell attachment observed when blocking α1 and α2. Significant and comparable decreases in 
HUVEC adhesion were observed when blocking integrin subunits αv (27.5%) and α5 (38.2%) with 
cell attachment almost fully eliminated with combination αv + α5 blocking (10.4%). As expected, 




adhesion was partially reduced (37.0%) when blocking only the integrin subunit α2 (Figure 2.3C). 
There was no significant decrease when blocking only integrin subunit αv but adhesion was 
reduced to less than 20% when blocking α2+αv+α5 in combination. When blocking integrin 
subunits on Scl2GFPGER hydrogels that target α1β1 and α2β1, there was no significant reduction in 
adhesion when blocking α5 or α1 (Figure 2.3D). Adhesion was reduced to less than 10% when 
blocking α2, and less than 5% when α1 and α2 were blocked in combination. Therefore, the 
findings in our bioactive hydrogel model confirm specific integrin binding in which HUVECs bind 
primarily to PEG-Col hydrogels with integrin α2β1 with other modes minorly contributing to 
attachment, bind primarily to PEG-Scl2GFPGER hydrogels with integrins α2β1, bind primarily to 
PEG-Gel hydrogels with integrins α5β1 and αvβ3, and bind to the combination PEG-Col/Gel gels 






Figure 2.3: Attachment of HUVECs to extracellular matrix proteins with integrin antibody 
blocking. HUVEC integrins are blocked on A) collagen, B) gelatin, C) collagen+gelatin, and D) 
Scl2GFPGER hydrogels. Data shown is average ± standard error of the mean. The * indicated 




2.3.3 HUVEC hemostatic gene expression 
To test the hypothesis that integrin targeting affected hemostatic regulators, HUVEC gene 
expression of von Willebrand factor (vWF), a disintigrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13 (ADAMTS-13), endothelial nitric oxide synthase 




(TFPI) was examined after attachment to each substrate. Each marker was selected based on 
established roles in hemostasis (Table 2.2). The pro-thrombotic regulators selected were vWF, 
which mediates platelet adhesion, and TF, which initiates thrombin formation.29,38 The anti-
thrombotic regulators selected were, ADAMTS-13 as an agonist of vWF by cleaving ultra-long 
chains,29,67,150 eNOS that generates the key anticoagulant of nitric oxide (NO), tPA as a protease 
responsible for breakdown of clots, and TFPI as an inhibitor of TF 29,38 In this study, vWF evenly 
expressed in HUVECs grown on PEG-Col, PEG-Gel, and PEG-Col/Gel with mixed integrin 
interactions, and lowest in HUVECs grown on PEG-Col and PEG-Scl2GFPGER that targeted 
integrins α1β1 and α2β1 (Figure 2.4A). HUVECs grown on combination PEG-Col/Gel gels 
exhibited expression levels intermediate to the PEG-Col and PEG-Gel. There was no observed 
increase in expression of TF on PEG-Gel hydrogels but the lowest expression in HUVECs was 
observed on PEG-Col hydrogels (Figure 2.4B). Unexpectedly, TF was most highly expressed in 
HUVECs grown on Scl2GFPGER hydrogels.  
The expression of anti-thrombotic regulators was also dependent on which substrate the 
HUVECs attached. All of the hydrogels induced upregulation of ADAMTS-13, eNOS, and tPA in 
adhered HUVECs but only the PEG-Scl2GFPGER hydrogels supported upregulation of TFPI (Figure 
4C-F). The highest expression of ADAMTS-13, TFPI, and tPA was observed in HUVECs adhered 
to PEG-Scl2GFPGER hydrogels. Although not statistically significant from the other substrates, 
eNOS was most highly expressed in HUVECs grown on PEG-Col hydrogels. Gene expression of 
anti-thrombotic regulators was statistically similar on PEG-Gel and PEG-Col/Gel hydrogels. 




regulation with differential expression of prothrombotic and antithrombotic regulators with 
different integrin interactions. These changes are summarized in Table 2.3.  
 
Table 2.2: Hemostatic regulators measured in gene expression analysis. 
 Protein Function 
Prothrombotic 
Proteins 
Von Willebrand Factor (VWF) 
Binds platelets to form platelet 
thrombi when in ultra-large 
multimer form [da Silva 2016] 
Tissue Factor (TF) 
Surface protein expressed by 
activated endothelial cells to initiate 
coagulation cascade [White 2010] 
Antithrombotic 
Proteins  
A disintegrin and 
metalloproteinase with a 
thrombospondin type I motif, 
member 10 (ADAMTS-13) 
VWF cleaving enzyme [Shim 2008] 
Tissue factor pathway inhibitor 
(TFPI) 
Major inhibitor of TF, Factor Xa, 
and thrombin [White 2010] 
Tissue plasminogen activator 
(tPA) 
Regulator of fibrinolysis [Booyse 
1999] 
Endothelial nitric oxide 
synthase (eNOS) 
Synthesizer of nitric oxide that 







Figure 2.4: HUVEC gene expression of hemostatic regulators. All values have been normalized 
to TCPS GAPDH. HUVEC gene expression varies on collagen, gelatin, combination, and DC2 
hydrogels. Genes investigated were for vWF (A), tissue factor (B), ADAMTS-13 (C), tissue factor 
pathway inhibitor (D), endothelial nitric oxide synthase (E), and tissue plasminogen activator (F). 
* represents significance between groups. Significance was determined by a 1-way ANOVA with 








Table 2.3: Relative change in gene expression of HUVEC hemostatic regulators. Fold change is 
represented by: “↓” = 0.5-0.8, “-” = 0.8-1.2, “↑” = 1.2-2, “↑↑” = 2-5, “↑↑↑” = >5. 
  PEG-Scl2 PEG-Col PEG-Gel PEG-Col/Gel 
Prothrombotic 
vWF - ↑ ↑ ↑ 
TF ↑ ↓ - - 
Antithrombotic 
ADAMTS-13 ↑↑↑ ↑↑↑ ↑↑ ↑↑ 
TFPI ↑↑ - - - 
eNOS ↑ ↑↑ ↑ ↑ 
tPA ↑↑ ↑ ↑ ↑ 
 
 
2.3.4 Platelet adhesion 
 To interrogate the hemostatic functional outcome of integrin targeting, we performed 
platelet adhesion studies with a protocol adapted from Baloaing et al.106 The lowest relative levels 
of platelet adhesion to HUVECs cultured on hydrogel substrates were observed on the PEG-Col 
and PEG-Scl2GFPGER hydrogels (Figure 2.5). The highest relative platelet adhesion was observed 
on HUVECs cultured on the PEG-Gel hydrogel. HUVECS cultured on the combination PEG-
Col/Gel were intermediate to the PEG-Col and PEG-Gel substrates. These results indicate that the 
HUVEC substrate can indeed be designed to reduce platelet attachment to the endothelial layer by 






Figure 2.5: Platelet attachment to HUVECs cultured on bioactive hydrogels. Platelets were 
isolated from whole blood and allowed to adhere to HUVECs after stimulation. Data shown is 
average ± standard deviation. The * indicated significance between groups, as determined by 1-




Endothelialization is a key strategy used to achieve sustained thromboresistance of blood-
contacting devices without using anticoagulants. To this end, biomaterials must be designed to 
achieve both a confluent endothelial layer and a hemostatic phenotype in the adhered cells. 
Previous studies have investigated endothelial cell hemostatic regulation differences on various 
ECM components and mimics, but often fail to differentiate the individual and synergistic effects 
of the integrins under investigation and their effects on endothelial hemostatic regulation.115,116,119 
To elucidate the relationship between select integrin targeting and HUVEC hemostatic regulation, 
we developed a bioactive hydrogel platform to isolate integrin interactions using PEG-based 
hydrogels enriched with collagen, gelatin, and the recombinantly expressed collagen-like protein 
Scl2GFPGER.  
We first established with integrin antibody blocking that these hydrogels target the desired 




gelatin and collagen bind to these integrins, but a comprehensive blocking study including these 
proteins and the Scl2GFPGER incorporated into hydrogels had not been previously reported.81,151 
These integrins proved to be the main modes of attachment, with other modalities likely making 
only minor contributions to attachment but also possibly influencing cell behavior. This is 
highlighted by the comparison between PEG-Col integrin blocking and PEG-Scl2GFPGER integrin 
blocking. When blocking the main modes of attachment, α1β1 and α2β1, on the PEG-Col hydrogel 
(Figure 2.3A), approximately 17% of cells remained, indicating that other modes of attachment 
contribute to cell adhesion and signaling. In comparison, when blocking the same integrins on 
PEG-Scl2GFPGER, cell adhesion was virtually eradicated. This highlights the ability of the PEG-
Scl2GFPGER platform to isolate only the integrins α1β1 and α2β1, whereas collagen has other 
attachment and signaling that can contribute to hemostatic regulation. Additionally, although not 
statistically different, the α1 integrin blocking appears to have more of an effect on HUVEC 
attachment on PEG-Scl2GFPGER than on PEG-Col hydrogel (Figure 2.3A, Figure 2.3D). This could 
be due to symbiotic syndecan attachment on collagen that can help to compensate other attachment 
modalities when α1 is blocked.82 However, both platforms are demonstrated to mediate HUVEC 
adhesion primarily through α2β1 interactions. This follows the integrin expression analysis where 
α2β1was the most highly expressed integrin on the HUVEC surface (Figure 2.2). It was also 
demonstrated that the PEG-Gel platform primarily targeted α5β1 and αvβ3, with each contributing 
equally to HUVEC attachment (Figure 2.3B). This again follows the integrin expression analysis 
where both integrins had similar expression levels. Similar to PEG-Col, however, some cells 





The other integrins associated with collagen attachment do not appear to be modes of adhesion 
as demonstrated by no change in attachment when blocking the integrin subunit α2. The PEG-
Col/Gel appears to target both the integrins targeted in each PEG-Col and PEG-Gel. This is 
demonstrated by the reduction in attachment by blocking integrin subunit α2, and the further 
reduction in attachment by blocking α2+α5+αv (Figure 2.3C). Although all of the main integrins 
that mediate attachment to this combination platform are blocked, 18% of cells remained attached. 
This indicates that there are other minor modes of attachment that remain in this platform that 
could affect some intra-cellular signaling. Overall, the integrins interrogated appear to be the main 
modes of attachment and likely the main mediators of signaling in the HUVECs. Few of the 
previous assessments of endothelial cell hemostatic regulation have carefully controlled the modes 
of attachments, often utilizing broad ECM protein coatings.115 Those that do have more specific 
targeting often use short peptide sequences such as RGD or other mimics of cell adhesive ligands 
found in the ECM but lack a thorough investigation of multiple common integrins used in 
endothelial cell binding to the ECM.106,116 
Through use of this platform, the data demonstrate that specific integrin targeting modulates 
HUVEC gene expression of hemostatic regulators (Figure 2.4). The hypothesis that specific 
binding in endothelial cells can affect hemostatic regulator gene expression and functionality is 
supported by previous studies.106,119 However, none provided a comprehensive analysis of many 
integrins and their effects on a broad range of potential hemostatic regulators.115 Here, we have 
investigated the effects of binding α1β1, α2β1, α5β1, and αvβ3 on HUVEC expression of vWF, 
TF, ADAMTS-13, TFPI, eNOS, and tPA. Overall, the HUVECs exhibited generally 
antithrombotic phenotypes when cultured on the bioactive hydrogel platforms (Table 2.3). There 




cells adhered to different bioactive hydrogels. vWF, a strong prothrombotic factor that directly 
attaches to platelets, had the lowest expression by targeting α1β1 and α2β1 compared to targeting 
integrins α5β1 and αvβ3 as well as all integrins in combination. The expression level of vWF is 
lowest in HUVECs with integrin targets α1β1 and α2β1 on the Scl2GFPGER hydrogel, in which there 
are no other mechanisms of attachment, like those remaining in collagen. This decrease in vWF 
on PEG-Scl2GFPGER compared to collagen has been previously reported by Munoz-Pinto et al and 
serves to confirm this trend.119 There is an increase in TF expression in HUVECs on PEG-
Scl2GFPGER compared to the other platforms, but this is complimented by a similar increase in 
relative expression of the TF agonist TFPI on PEG-Scl2GFPGER. This may possibly offset the effects 
of each, with no net effect on thrombogenicity. There is also an increase in ADAMTS-13 and tPA 
on PEG-SCl2GFPGER compared to the other platforms that indicate that by targeting α1β1 and α2β1 
alone, there is an increase in anti-thrombotic response in HUVECs. The gene expression of eNOS, 
a synthesizer of nitric oxide, appears to be most highly expressed on the collagen platform, with 
the next highest expression on Scl2GFPGER. However, there is no significant difference between the 
groups. Again, in comparing collagen and Scl2GFPGER in hydrogels, Munoz-Pinto et al. found no 
significant difference in NOS3 expression, a similar synthesizer of NO in endothelial cells.119 
Overall, it appears that by targeting integrins α1β1 and α2β1, HUVECs will exhibit a more 
thromboresistant phenotype than by targeting the integrins α5β1 and αvβ3 or a combination 
thereof, though targeting any of these integrins appears to promote thromboresistance.  
These gene expression trends are confirmed in the functional assays of platelet adhesion. 
Previous studies have demonstrated correlation of hemostatic gene expression to the protein 
expression.106,119 Therefore it was expected that the platelet adhesion trends would follow the 




HUVECs by targeting integrins α5β1 and αvβ3 with PEG-Gel and PEG-Col/Gel hydrogel 
platforms. Comparatively, there appears to be lower relative platelet attachment to HUVECs when 
targeting integrins α1β1 and α2β1 with the Scl2GFPGER and collagen hydrogels (Figure 2.5). This 
indicates that the largely thromboresistant phenotype of the HUVECs that was measured when 
targeting integrins α1β1 and α2β1 has a similar functional outcome, with fewer platelets adhered 
to these cells. In particular, the gene expression of vWF appears to be most predictive of the trend 
in adhered platelets (Figure 2.4A). This is likely due to the ability of vWF to bind directly to 
platelets without other intermediaries, but other prothrombotic factors like TF require a cascade to 
affect platelet activation and aggregation.30,150 Overall, the results indicate that specific integrins 
can be used for attachment and thromboresistant signaling in endothelial cells. 
 These specific integrin targets can be used to tailor biomaterials to not only promote 
endothelial cell adhesion, they can be used to promote a thromboresistant phenotype in adherent 
cells. Specifically, previous work has demonstrated that Scl2 proteins can be produced to target 
specific integrins such as α1β1 and α2β1 while remaining themselves thromboresistant, a distinct 
advantage over other proteins such as collagen and gelatin.122 Additionally, they have previously 
demonstrated increased endothelial cell migration compared to collagen.54 This creates unique 
tools to design blood-contacting materials to promote thromboresistance via post-implantation 
endothelialization. This strategy can be utilized in cardiovascular device design, such as a 
previously described multi-layer vascular graft.86 The specific integrin targeting of the naturally 
thromboresistant Scl2GFPGER incorporated into a hydrogel lining of the graft promotes long term 







We and others have demonstrated that endothelial cell attachment and migration is 
mediated by the ECM substrate.28,53,54,87,88,152 The work presented here demonstrates the ability to 
influence endothelial cell hemostatic regulation through specific integrin targeting. Overall, 
HUVECs exhibited a more thrombogenic phenotype on bioactive hydrogels that targeted integrins 
α5β1 and αvβ3. The functional outcome of this increased thrombogenic gene expression in vitro 
is an increase in platelet adhesion. By specifically targeting α1β1 and α2β1, where platelet 
adhesion was lower, we can promote a more thromboresistant phenotype, ideal for coating blood 
contacting surfaces in medical devices. This specific targeting can be accomplished through the 
use of Scl2GFPGER, as demonstrated in the antibody integrin blocking study. The ability to target 
specific integrins enables the design of thromboresistant biomaterials. Future work will include 
adding other factors to the platform, such as a shear component, to better mimic in vivo conditions 
as well as determine the dominant factor that contributes to endothelial cell hemostatic regulation. 
The validity of this platform will ultimately be tested by in vivo evaluation of endothelial cell 




CHAPTER III  
ELUCIDATING THE ROLE OF GRAFT COMPLIANCE MISMATCH ON INTIMAL 
HYPERPLASIA USING AN EX VIVO ORGAN CULTURE MODEL 
 
3.1 Introduction 
After addressing failures due to thrombosis, we continue to improve the multialyer graft by 
addressing another critical limitation of synthetic vascular grafts: re-occlusion due to intimal 
hyperplasia. The high rate of failure due to intimal hyperplasia has been correlated with a 
compliance mismatch between the grafting material and the native vasculature.132,140 Despite this 
strong empirical correlation, the mechanisms by which compliance mismatch leads to intimal 
hyperplasia are relatively poorly understood. It is theorized that the compliance mismatch leads to 
a flow disruption at the distal anastomosis, which then leads to low wall shear stress.132,141 The 
vessel wall, in response to the low wall shear stress, attempts to correct the flow disruption with 
intimal thickening, ultimately leading to re-occlusion of the vessel.140 In order to design vascular 
grafts with improved patency, the complex cascade of events that begins with changes in the 
endothelium and initiates the smooth muscle cell phenotypic alterations that typify intimal 
hyperplasia need to be elucidated.   
It has been difficult to directly relate compliance-mismatch and the resulting changes in fluid 
dynamics to the development of intimal hyperplasia because of confounding factors of graft 
properties. For example, the often cited high-compliance grafts with improved patency are 
autografts as compared to the low-compliance synthetic grafts.140 Isolation of the effect of 
compliance is ideally conducted on synthetic grafts that can vary compliance independent of other 




tunable biomechanical properties and improve compliance matching that enables this 
investigation.86 In addition, to elucidate the role of compliance on the change in blood flow, a 
quantitative prediction of the change in wall shear stress as a function of graft compliance is 
needed. Computational models have been used to predict changes in blood flow and wall shear 
stress in stenting of coronary arteries to improve the design iteration process for vascular stents.153-
155 It has also been used to investigate how different anastomosis techniques affect flow between 
the graft and the native vasculature to determine the optimal surgical method.156,157 In this study, 
we propose to use a computational model of the synthetic graft-artery anastomosis to provide a 
prediction of wall shear stress as a function of graft compliance that can be directly correlated to 
changes observed in distal arterial remodeling. Finally, evaluation of vascular grafts includes 
assessment of long-term patency and incidence of intimal hyperplasia using large animal models 
that can be both time and cost-prohibitive.158 A method to rapidly screen vascular grafts for early 
markers of intimal hyperplasia using an ex vivo organ culture model would enhance vascular graft 
development.  
In the current study, a unique ex vivo organ culture model was developed to analyze the 
histological changes in grafted porcine carotid arteries in response to an increased compliance 
matching of the grafts. First, grafts of distinct compliances were fabricated and compliance was 
evaluated before suturing to the carotid arteries and culturing in the ex vivo bioreactor.86 The distal 
anastomoses were analyzed after two weeks of culture for changes in the endothelium (VE-
Cadherin, vWF, N-Cadherin), VSMC phenotype (SM22α, SMα-actin, N-Cadherin, and 
proliferation marker Ki67), and extracellular matrix composition (versican, elastin, fibronectin), 
as early markers of intimal hyperplasia. Finally, these findings were correlated to a predictive 




the graft. This study elucidates not only the intrinsic link between graft compliance mismatch and 
the development of intimal hyperplasia, it also provides a screening method for synthetic small 
diameter vascular graft development. It also allowed for the identification of a high compliance 
graft that limits the development of intimal hyperplasia for the outer layer of the multilayer 
vascular graft. 
3.2 Results and Discussion 
3.2.1 Varying graft compliance 
We have demonstrated the ability to fabricate multilayer vascular grafts with increasing 
compliance, exceeding that of the saphenous vein, independent of other factors such as graft 
chemistry and cellular interactions.86 For this study, we selected grafts with a low compliance (~2 
%/mmHg x 10-2) to mimic the ePTFE clinical control, medium compliance (~5 %/mmHg x 10-2), 
and high compliance (~8 %/mmHg x 10-2) to closely match the compliance of the native carotid 
artery to be used in the ex vivo bioreactor system. Bionate® thermoplastic poly(carbonate-
urethane) was electrospun with careful control of graft thickness and fiber morphology to meet 
design criteria. Increasing electrospinning collection time from 2 hours to 6 hours resulted in grafts 
that were 0.4, 0.3, 0.2, and 0.1 mm thick with corollary compliances of 3.4 ± 1.1, 4.1 ± 0.3, 7.3 ± 
1.3, and 8.1 ± 0.3 %/mmHg x 10-2, respectively (Figure 3.1B). The measured compliance of the 
ePTFE control, determined by the same methodology, was 1.6 ± 0.2 %/mmHg x 10-2. The grafts 
retained burst pressures comparable to the saphenous vein and appropriate suture retention 
strengths (Figure 3.1 C, D). Electrospun meshes with target biomechanical properties were then 






Figure 3.1: A) Effect of modulating collection time on graft thickness as demonstrated by SEM. 
Compliance (B) and burst pressure (C), and suture retention strength (D) of the low, medium, and 
high compliance grafts compared to the clinical control ePTFE. Data is represented as average ± 
standard deviation for n=6. Statistical significance is shown by * showing significance from all 
other measured values, with p<0.05. LV: Literature value from Mun et al. and Mine et al.  
 
 
3.2.2 Computational modeling 
A computational model was created to illustrate the changes in flow as a function of 
compliance and estimate the resulting changes in wall shear stress at the distal anastomosis of the 
high, medium, and low compliance grafts (Figure 3.2). Turbulent flow was apparent in the low 
compliance graft model with flow recirculation distal to the graft with a corollary wall shear stress 
of 0.03 N/m2 at 80mmHg and 0.03 N/m2 at 120 mmHg. These values approached zero near the 
zone of recirculation at the distal anastomosis. The observed turbulence was reduced in the 
medium compliance model, with the wall shear stress calculated to be 1.04 N/m2 at 80mmHg and 
1.08 N/m2 at 120mmHg. The high compliance graft eliminated turbulent flow with wall shear 





Figure 3.2: A. Effect of compliance on flow patterns and wall shear stress at the distal anastomosis 
as determined by the computational model made in COMSOL. Linear flow patterns demonstrate 
decreasing flow disruption with increasing compliance. B. Lower compliance correlates to lower 
wall shear stress. Threshold from Sho et al. 2004. 
 
 
The computational model demonstrated the blood flow profile changes and changes in wall 
shear stress between grafts of different compliances. The differences in compliance lead to 




the low compliance grafts have the greatest difference in diameter and therefore the largest effect 
on the blood flow profile, creating zones of blood recirculation and low wall shear stresses that are 
associated with the development of intimal thickening in other small animal models 159.  As 
compliance increases, the dilation changes between the graft and the native artery decrease, 
preserving flow lines. This in turn increases wall shear stress. Therefore it is expected that grafts 
with low compliance may induce intimal hyperplasia based on the computational model 
predictions, and grafts with higher compliance may mitigate those effects. 
3.2.4 Ex vivo bioreactor immunohistochemistry 
The ex vivo bioreactor model allows for simplification of a complex in vivo system. Porcine 
carotid arteries sutured to multilayer grafts (Figure 3.3A) of low, medium, and high compliance 
as well as an artery-artery sham control and the ePTFE clinical control were cultured for two 
weeks. The ex vivo bioreactor system subjected the sutured grafts and arteries to physiological 
pulsatile flow for two weeks in enriched culture medium (Figure 3.3B). The analysis of the 
histology of the arteries sutured to grafts of increasing compliance demonstrate a decrease in 
markers for intimal hyperplasia (Figures 3.4-7).  In general, the arteries sutured to the low 
compliance graft and the ePTFE control exhibited similar staining for early markers of intimal 
hyperplasia, whereas the arteries sutured to the high compliance grafts displayed similar staining 






Figure 3.3: A) Inner and outer layers of the multilayer graft. B) Ex vivo organ culture system.   
 
 
In comparing VSMC phenotype, greater spatial heterogeneity in SMα-actin staining was 
observed in the lower compliance groups relative to the sham control (Figure 3.4).  In addition, 
regions of intense staining for SM22α (Figure 3.4) as well as for Ki67 and N-Cadherin (Figure 
3.5) within the medial layer were noted with increased intensity and frequency with decreasing 
graft compliance. In contrast, N-Cadherin staining in the endothelium was increased in all 
synthetic graft groups relative to the sham control (Figure 3.6), although the increase was modest 
for the high compliance group. Similarly, no differences in VE-Cadherin staining were observed 
across groups. However, vWF staining displayed a clear and consistent increase with higher 
degrees of compliance mismatch. Furthermore, the low compliance treatment group and ePTFE 
control group demonstrated vWF staining penetrating into the vessel wall, as is often observed in 





Figure 3.4: The effect of compliance on smooth muscle cells at the distal anastamosis as 
demonstrated by histological staining of SMα-actin and SM22α at day 14. The images presented 




Figure 3.5: The effect of compliance on the smooth muscle cells at the distal anastomosis by 
histological staining of Ki67 and N-Cadherin at day 14. The images presented are representative 






Figure 3.6: The effect of compliance on endothelial cell behavior at the distal anastomosis by 
histological staining of N-cadherin, VE-Cadherin and vWF at day 14. The images presented are 




To examine alterations in medial layer extracellular matrix associated with these 
differences in VMSC and endothelial cell behavior, staining for “acute” markers MMP-1 and 
versican was conducted (Figure 3.7). MMP-1 staining –particularly in the subintimal space – 
increased as graft compliance decreased. Similarly, versican staining displayed higher subintimal 
intensity as well as increased spatial variation in the low compliance treatment groups. In contrast, 
staining for elastin and fibronectin - extracellular matrix markers associated with more progressed 





Figure 3.7: The effect of compliance on the extracellular matrix of the vessel media at the distal 
anastomosis by histological staining of MMP-1 and versican at day 14. The images presented are 




Figure 3.8: The effect of compliance on extracellular matrix proteins at the distal anastomosis 
by histological staining of elastin and fibronectin at day 14. The images presented are 








3.2.3 Biostability of Synthetic Grafts 
As a final evaluation prior to proceeding to in vivo assessment of intimal hyperplasia using 
a porcine model, accelerated degradation testing was performed to confirm the biostability of the 
vascular grafts. Accelerated oxidative degradation in 0.1M CoCl2 and 20% H2O2 for 36 days at 
37°C was selected for its well-established use in mimicking macrophage-mediated oxidative 
degradation of polyurethanes.160 The compliance for the high, medium, and low compliance grafts 
were not significantly different after degradative treatment, Figure 3.9A. Similarly, the burst 
pressures were not significantly different for the high and medium compliance grafts; however, a 
small but significant loss of burst pressure was observed for the low compliance graft (Figure 
3.9B). The suture retention strength for the grafts also remained largely unaltered by degradative 
treatment (Figure 3.9C). No notable change in fiber morphology of the meshes was observed with 
scanning electron microscopy and no notable change in surface chemistry as monitored with ATR-
FTIR spectroscopy was observed after degradative treatment. There was some salt precipitate 
apparent in the treated samples even after washing and drying. (Figure 3.9D,E). Overall, the 
biomechanical properties of the vascular grafts were retained after accelerated oxidative 
degradation. These findings in combination with previous studies that confirmed the 
thromboresistance of the multilayer grafts support the safety of the constructs for long-term 
implantation studies.86 Notable for the continuation of this work is that these findings indicate that 






Figure 3.9: The effects of accelerated oxidative degradation for 36 days in 0.1M CoCl2 in 20% 
H2O2 on the compliance (A), burst pressure (B), and suture retention strength (C) of the low, 
medium, and high compliance multilayered vascular grafts. The effects of oxidative degradation 
on fiber morphology determined by SEM (D) and surface chemistry determined by ATR (E). 
Statistical significance is shown by * to show a difference between untreated and degraded 




Intimal hyperplasia contributes to the high failure rates of synthetic vascular grafts currently 
available to clinicians. Elucidating the mechanism that graft compliance mismatch initiates intimal 
hyperplasia has been clinically difficult due to many confounding factors such as varying graft 
compositions and confounding diseases. Despite some of these challenges, low wall shear stress 




compliance mismatch between the vascular graft and the native vasculature disrupts blood flow 
and creates zones of blood recirculation. Our ability to fabricate grafts with varying compliance 
independent of other variables allowed for a direct correlation of changes in wall shear stress due 
to poor compliance matching and early markers of intimal hyperplasia in a novel ex vivo organ 
culture model. The tools we have developed for these studies not only enable the investigation of 
intimal hyperplasia, they also allow for efficient future graft design iterations. The computational 
model also allows for optimization of graft parameters to limit turbulent flow and maintain high 
wall shear stress at the distal anastomosis. Future versions of the computational model could 
include more complex arterial geometries to better predict flow and wall shear stress in vivo. 
Finally, the ex vivo system can be used to quickly screen vascular graft prototypes for their 
propensity to induce early markers of intimal hyperplasia. Future work will build on the current 
studies by examining the long term effects of compliance mismatch in a large animal model and 
correlate these findings to the ex vivo bioreactor screening. 
 
3.4 Materials and Methods 
3.4.1 PEGDAA synthesis 
Polyethylene glycol diacrylamide (PEGDAA) was synthesized according to a method 
adapted from Hahn, et al.149 Briefly, acryloyl chloride (4 molar equivalents) was added dropwise 
to a solution of PEG diamine (3.4 kDa; 1 molar equivalent) and triethylamine (TEA, 2 molar 
equivalents) in anhydrous dichloromethane (DCM) under nitrogen. The reaction was stirred for 24 
hours, and then washed with 2M potassium bicarbonate (8 molar equivalents). After drying with 
anhydrous sodium sulfate, the product was precipitated in cold diethyl ether, vacuum filtered, and 




3.4.2 Multilayer graft fabrication 
A 25 wt% solution of Bionate® thermoplastic polycarbonate-urethane (DSM Biomedical) 
in dimethylacetamide was electrospun with a flow rate of 0.5 ml/hr through a blunted 20G needle. 
The rotating mandrel for collection was first coated in a PEG sacrificial layer and placed 50 cm 
from the needle tip. A voltage of 15 kV was applied to the needle and a -5kV voltage was applied 
to the rotating mandrel. Mesh thickness was varied from 0.1–0.4 mm by adjusting collection time. 
The rod and mesh were allowed to soak for 1 hour in water to dissolve out the sacrificial PEG 
layer, and the mesh sleeve was cut into 4 mm long sections. Electrospun mesh sleeves were then 
taken through a graded ethanol/water soak (70%, 50%, 30%, and 0%; 30 minutes each) to ensure 
hydration and penetration of the aqueous hydrogel precursor solutions into the mesh prior to 
hydrogel coating. The pre-wetted meshes were then placed in a cylindrical mold with an inner 
glass mandrel (4 mm outer diameter). The hydrogel precursor solution (7.2% PEGDAA, 3.6% n-
vinyl pyrrolidone (NVP), and 1% Irgacure solution) was pipetted between the mandrel and the 
hydrated mesh and crosslinked with UV light for 6 minutes in a custom-built UV box. Composite 
grafts were then soaked for three days with daily solution changes to remove un-reacted NVP. 
3.4.3 Computational modeling 
Simulations were performed with the software package COMSOL Multiphysics. The 
geometry used to simulate the graft was an axial model that can be rotated 360 degrees to yield a 
3D representation of the grafted vessel. The vessel on each end were modeled with no slip 
boundaries and a compliance of 9.0 %/mm Hg x 10-2, 10 cm long and 4 mm inner diameter. The 
graft was modeled with increasing compliances 1.5, 4.0, and 8.5 %/mm Hg x 10-2, 4 cm long and 
4 mm inner diameter. Blood flow was modeled using the Carreau Yasuda model of blood viscosity: 









Fluid flow through the fixed inlet was set at physiological parameters at 395 ml/min and pressure 
varied from 80 to 120 mmHg. Using Fluid-Solid Interaction physics and the Fluid Flow physics, 
wall shear stress (WSS) was calculated from the flow rate at the walls. 
3.4.4 Organ culture 
Fresh porcine carotid arteries were purchased from LAMPIRE Biological Laboratories, 
Inc. (Pipersville, PA). Arteries were dissected in a laminar flow hood to remove excess of 
connective tissue and rinsed multiple times with PBS containing antibiotics and antimycotics 
(PBS-PSA, Gibco) to check for leaking or small side branches. Arteries were then sectioned into 
three pieces distributed as follows: two 2cm length pieces at both ends of the artery and a central 
2mm length piece that would be used to assess the initial morphology and protein expression of 
the artery. The two 2cm segments were then anastomosed using a 7-0 prolene surgical needle 
(Ethicon) to different grafts; 1) multilayer grafts of low compliance, 2) multilayer grafts of medium 
compliance, 3) multilayer grafts of high compliance, 4) ePTFE grafts control (GORE-TEX® 
Stretch Vascular Graft ST04015A) and 5) segments of artery alone, used as negative control. The 
grafted vessels with a structure of artery-graft-artery or artery-artery-artery were then sealed using 
surgical glue (Coseal, Baxter) rinsed with PBS-PSA to check for flow and leaking, mounted on a 
bioreactor chamber (BISS Tissue Growth Technologies) and fixed into place using a sterile nylon 




for any leaking. Complete Endothelial Growth Media (EGM; DMEM + 20% BCS+ 2%PSA+ EGF 
+ bFGF + VEGF + Long R3 IGF + Ascorbic Acid + Heparin + Hydrocortisone) was placed inside 
the artery chambers while the lumen of the grafted vessels was perfused with EGM supplemented 
with 35 mg/ml of Pharmaceutical Grade Dextran (Dextran T70, Pharmacosmos). Vessels were 
then cultured with a constant flow rate of 30 ml/min generated by a peristaltic pump (Masterflex 
L/S 07528-30) for 14 days at 37°C and 5% CO2 changing media every other day. The peristaltic 
pump resulted in a pulsatile waveform and pressure in the system was adjusted to achieve ~120 
mmHg/80 mmHg peak-to-trough pressures. 
Vessels were collected at day 0 or after 14 days of culture and fixed with 10% buffered 
formalin (Fisher) overnight at 4°C. For the grafted vessels after 14 days of culture, portions of the 
arteries at both distal and proximal anastomosis sites (2 mm length) were selected for analysis. 
Day 0 samples and selected 14 days samples were then embedded in OCT and cryosectioned at 5 
µm thickness for immunoshistochemical analysis.  
3.4.5 Immunohistochemistry 
Protein expression was analyzed using standard immunohistochemical techniques. 
Sections were rehydrated at room temperature for 15 minutes, then endogenous peroxidases were 
blocked for 10 minutes followed by the addition of the background terminator solution to block 
nonspecific background staining (BioCare Medical) for 10 minutes. Sections were then incubated 
with the appropriate primary antibody for 1 hour at room temperature (Table 3.1). The binding of 
the primary antibody was detected by incubating the samples with HRP-conjugated secondary 
antibodies (Jackson ImmunoResearch) for 1 hour at room temperature followed by the application 
of the DAB chromogen (Vector Laboratories). Stained sections were imaged using a Zeiss 




Table 3.1: Primary antibodies used for histological analysis. 
Protein Marker Clone number Source 
SMα-actin 1A4 (mouse) SCBT 
SM22α ab14106 (rabbit) Abcam 
Ki67 NB500 (rabbit) Novus 
N-Cadherin K20 (goat) SCBT 
vWF H300 (rabbit) SCBT 
VE-Cadherin C19 (goat) SCBT 
MMP-1 N17-R (rabbit) SCBT 
Versican 12C5 (mouse) DSHB 
Elastin BA4 (mouse) SCBT 
Fibronectin EP5 (mouse) SCBT 
*SCBT- Santa Cruz Biotechnology 
 
 
3.4.6 Oxidative degradation and mechanical testing 
 Accelerated oxidative degradation testing was utilized to assess the biostability of the 
electrospun outer layer. Composite vascular grafts of high, medium, and low compliance (n = 4 
for each) were placed in an oxidative solution of 0.1M CoCl2 and 20% H2O2 for 36 days at 37°C 
with solution changes every 3 days to maintain a relatively constant concentration of radicals. The 
effect of the oxidative treatment on the graft compliance, burst pressure, suture retention strength, 
fiber morphology, and surface chemistry was then characterized. Compliance was measured by 
first inserting latex tubes into 5 mm long graft segments and connecting to a syringe pump with a 
flow rate of 2 ml/min. The diameter of the graft was measured using a laser micrometer (1210 
Laser Micrometer, Z-Mike) at 80 and 120 mmHg. Compliance (C) was calculated by C = 
ΔD/D0•ΔP = (D120 – D80)/D80•40 as per the Niklason group (ref). Flow rate was then increased to 
50 ml/min with obstructed flow until the outer layer burst. The highest pressure measured at the 
first sign of graft bursting was recorded as the burst pressure. Graft composites were cut lengthwise 




mesh. The un-sutured end was secured in the bottom clamp and the top suture was secured in the 
upper clamp. Uniaxial strain was applied at a rate of 100 mm/min until the suture was pulled 
through the mesh. The maximum applied force was recorded as the suture retention strength. 
The effect of oxidative degradation on the polyurethane mesh on surface chemistry and 
topography was determined using attenuated total reflectance- Fourier transform infrared (ATR-
FTIR) spectroscopy and scanning electron microscopy (SEM). Meshes were washed and dried 
under vacuum overnight prior to testing (n = 4). Spectra were recorded using a Nicolet iS10 
(Thermo Scientific) FTIR spectrometer at a resolution of 2 cm-1 for 64 scans using an ATR 
accessory with a germanium crystal. The fiber morphology was observed using SEM (Phenom 
Pro, NanoScience Instruments) at 10 kV accelerating voltage. Specimens approximately 5 mm x 
5 mm were cut from each sample and mounted with conducting carbon tape on a cylindrical SEM 
stub (n = 4). Prior to imaging, the specimens were coated with 4 nm of gold using a sputter coater 





CHAPTER IV  
INTRODUCTION OF SACRIFICIAL BONDS TO HYDROGELS TO INCREASE DEFECT 
TOLERANCE DURING SUTURING OF MULTILAYER VASCULAR GRAFTS* 
 
4.1 Introduction 
In Chapter II and Chapter III, we described improvements to the cellular interactions and 
mechanical properties of the multilayer graft, but further improvements to the hydrogel inner layer 
are required. After implantation as end-to-end anastomosis into the carotid arteries of 6 month old 
swine, damage to the hydrogel coating of the composite graft was observed, as demonstrated in 
Figure 4.1. The generation of hydrogel particulates during suturing of the grafts represents a 
significant risk that must be addressed prior to further graft development and assessment. The risks 
associated with dislodged hydrogel particulates are similar to those of a thrombus or embolus and 
include stroke, heart attack, and pulmonary embolism.161 There is a clear need for a hydrogel 
coating in the multi-layered small diameter vascular graft that does not generate particulates after 
suturing that can act as emboli downstream. However, no suture damage resistant hydrogels or 
requisite material properties have been described in literature to the best of our knowledge. We 
also found that common mechanical properties evaluated in hydrogels such as compressive and 
tensile modulus, toughness, and elongation did not correlate to particles dislodged during suturing. 
                                                 
* Reprinted with permission from “Introduction of sacrificial bonds to hydrogels to increase 
defect tolerance during suturing of multilayer vascular grafts” by Allison Post, Alysha Kishan, 
Patricia Diaz-Rodriguez, Egemen Tuzun, Mariah Hahn, Elizabeth Cosgriff-Hernandez, 2018. 




Due to the lack of hydrogels exhibiting suture damage resistance, we have developed a hydrogel 




Figure 4.1: A) Schematic of multilayer graft fabrication. B) Damage of the hydrogel at the 
suture line of multilayer graft composites implanted in porcine animal model. 
 
 
In order to resist suture damage, the hydrogel must be resistant to crack propagation 
initiated by passing a suture needle through it. This can be accomplished by increasing the energy 
required to initiate crack propagation by increasing the secondary force interactions between 
adjacent polymer chains.162 Enhancing secondary bonding or sacrificial bonds increases the energy 
required to initiate crack propagation through a material. Therefore, increasing hydrogen bonding 
can increase the defect tolerance in the hydrogel coating. We hypothesize that by introducing 
increased hydrogen bonding in the hydrogel, crack propagation and the associated dislodged 
particles will decrease. To this end, we enhanced hydrogen bonding by incorporating n-vinyl 
pyrrolidone (NVP) into the hydrogel to create a clinically relevant graft.  
A PEG-based hydrogel with enhanced hydrogen bonding was developed to prevent damage 
to the hydrogel coating during suturing of our vascular graft. Initially, the mechanical properties 




correlation to suture-induced damage. The hydrogel formulation with the fewest dislodged 
particles was then evaluated to confirm retention of thromboresistance, bioactivity, and biostability 
as compared to traditional poly(ethylene glycol) diacrylate (PEGDA) hydrogels. Finally, 
composite grafts were sutured into excised porcine carotid arteries and hydrogel particulate 
generation was evaluated in an ex vivo model under physiological flow. This study provides a 
comprehensive evaluation of this new hydrogel as a vascular graft coating that prevents 
complications associated with suture-induced particulate generation. 
4.2 Materials and Methods 
4.2.1 Materials 
Bionate® Thermoplastic Polycarbonate-urethane was provided by DSM Biomedical 
(Berkeley, CA). All other chemicals were purchased from Sigma Aldrich (Milwaukee, WI) and 
used as received unless otherwise noted. 
4.2.2 PEGDA and PEGDAA Synthesis 
Polyethylene glycol diacrylate (PEGDA) was synthesized according to a method adapted 
from Hahn, et al.149 Briefly, acryloyl chloride (4 molar equivalents) was added dropwise to a 
solution of PEG diol (3.4 kDa; 1 molar equivalent) and triethylamine (TEA, 2 molar equivalents) 
in anhydrous dichloromethane (DCM) under nitrogen. The reaction was stirred for 24 hours, and 
then washed with 2M potassium bicarbonate (8 molar equivalents). After drying with anhydrous 
sodium sulfate, the product was precipitated in cold diethyl ether, vacuum filtered, and dried under 
vacuum. Polyethylene glycol diacrylamide (PEGDAA) was prepared using a similar method to 
PEGDA. Briefly, acryloyl chloride was added to a solution of PEG diamine (3.4 kDa) and TEA in 
anhydrous DCM under nitrogen. The molar equivalent of PEG diamine, TEA, and acryloyl 








Figure 4.2: Chemical structures of A) poly(ethylene glycol) diacrylate (PEGDA) with an ester 
linkage, and of B) poly(ethylene glycol) diacrylamide (PEGDAA) with an amide linkage and n-




4.2.3 Hydrogel fabrication and characterization 
Several hydrogel compositional variables were tested including the effect of polymer 
backbone (PEGDA, PEGDAA), molecular weight (10kDa, 6kDa, 3.4kDa), crosslinker (NVP, 4-
arm PEG acrylate), and polymer concentration (3.6, 7.2, 10, 20, 30%). As a generalized fabrication 
method, hydrogel slabs were fabricated by dissolving PEGDA or PEGDAA in deionized water 
with 1 vol% of the photoinitiator Irgacure 2595 (10mg/ml in 70% ethanol). NVP was incorporated 
in select precursor solutions at the molar ratios 1:12, 1:24, or 1:54 of PEG:NVP. Samples 
containing 4-arm PEG-acrylate were prepared with 10% or 20% 4-arm PEG-acrylate added to the 
10% precursor solution of PEGDA. Precursor solutions were mixed and pipetted between 1.5 mm 
glass spacer plates and crosslinked on a UV plate, 6 minutes on each side.  
The sol fraction and swelling ratio was determined for each hydrogel composition (n = 6). 
Briefly, circular hydrogel specimens (D = 8 mm) were dried under vacuum immediately after 




(Ws),  and then weighed again after drying under vacuum for 24 h to assess dry polymer mass (Wd). 
The sol fraction was calculated as (Wi-Wd)/Wi. The equilibrium volumetric swelling ratio, Q, was 
calculated from the equilibrium mass swelling ratio: (Ws)/Wd. 
 
4.2.4 NVP incorporation 
An assay developed by El-Rabbat et al. was used to measure the quantity NVP leached out 
of the hydrogels as an indirect method to determine NVP incorporation into the polymer 
network.163 Briefly, 8 mm hydrogel punches (n = 6) were soaked for 3 days with daily solution 
changes to remove unincorporated NVP. The supernatant was frozen, lyophilized, and re-
suspended in 1 ml of glacial acetic acid. NVP was diluted in acetic acid to create the calibration 
curve. Malonic acid was dissolved at 10 wt% in acetic anhydride at 80°C for 5 minutes to create 
the working reagent. The working reagent was then added in equal volumes to the re-suspended 
hydrogel extracts and calibration solutions. The solutions were allowed to stand for 20 minutes at 
80°C and then fluorescence read on a plate reader with excitation/emission at 397nm/452nm. The 
amount of NVP leached out of the gels was calculated using the calibration curve. 
4.2.5 Hydrogel mechanical testing 
Mechanical testing was performed to determine the effect of compositional variables on 
the compressive and tensile properties of the hydrogels as well as crack propagation using a single 
edge notch test. Hydrogels of each composition were fabricated as described above. Compressive 
modulus was determined using a dynamic mechanical analyzer (DMA) (RSAIII, TA Instruments). 
Six 8-mm diameter discs were punched from swollen hydrogel sheets and subjected to mechanical 
testing using the DMA fitted with a parallel-plate compression clamp. Testing was performed 




determine the linear viscoelastic range for each hydrogel formulation. Then, a strain within the 
upper end of the linear viscoelastic range was used in a constant strain frequency sweep. Tests 
were conducted between 0.79 and 79 Hz, and the compressive storage modulus was taken at 1.25 
Hz. 
Tensile testing was performed on hydrogel rings that were fabricated by pipetting the 
precursor solution into a custom mold with a 3 mm inner diameter and a 5 mm outer diameter. The 
hydrogel tubes were swollen in deionized water for 24 h and then cut into 3 mm sections. Ring 
specimens (n = 6) were loaded in tension on an Instron 3324, and the stress and strain were 
recorded as the rings were pulled at a rate of 6 mm/min until failure. Tensile modulus was 
determined by the slope of the linear region of the stress-strain curve. Ultimate elongation was 
measured by the stretched length over the original length as a percent, or (L/L0)*100. Ultimate 
tensile strength was determined as the force at failure. Toughness was measured as the area under 
the stress-strain curve.  
To determine the fracture toughness of the hydrogel compositions, hydrogel specimens  
were fabricated (30 mm long, 10 mm wide, 1.5 mm thick) for single edge notch mechanical testing. 
Hydrogels fabricated with PEG(10k)DA, PEG(6k)DA, and PEG(3.4k)DA, each with and without 
NVP, were tested (n = 6). Using a razor blade, a notch 5 mm long was cut halfway along the length 
of the gel. The gels were then loaded into tensile grips of the RSAIII DMA using sandpaper to 
prevent hydrogel slippage. The gels were pulled in tension at 1 mm/s until the crack had propagated 
across the gel. The force of crack propagation was recorded and fracture toughness of the gel was 
calculated by the force over the length of the crack, G = 2F/h0. 




Suture-induced damage was determined by the number of particulates dislodged during the 
pass of a suture needle and thread through a hydrogel slab. Hydrogel slabs were fabricated as 
described above and soaked in deionized water for 12 h. A 7-0 suture (Ethicon) was passed through 
the hydrogel to assess the suture-induced damage. Dislodged hydrogel particles were visualized 
and counted under a stereoscope (National Optical) as a measure of suture-induced damage of the 
hydrogel. 
4.2.7 Bovine aortic endothelial cell (BAEC) adhesion to hydrogels 
Bioactivity was conferred to the hydrogels by adding 4 mg/ml of collagen functionalized 
with acrylate-PEG-NHS linker (JenKem) (functionalization of 10% of the available lysines) to the 
10% PEG(3.4k)DA and 20% PEG(3.4k)DAA-NVP hydrogel precursor solutions prior to cure. The 
hydrogels were soaked for 3 days prior to cell seeding to remove any uncrosslinked NVP. Circular 
specimens (D = 10 mm) were punched from hydrogel slabs and placed into a 48 well plate. Bovine 
aortic endothelial cells (BAECs) were cultured in EGM-2 cell media (Lonza), harvested for use at 
passage P4-P6, and seeded at 10,000 cells per well. Cells were allowed to attach for 3 hours, then 
washed twice with warm 10 mM phosphate buffered saline (PBS). Specimens were then fixed with 
3.7% glutaraldehyde and stained with rhodamine phalloidin (actin/cytoskeleton) and SYBR green 
(DNA/nucleus). Cell adhesion and spreading were quantified using ImageJ software (n = 4). 
4.2.8 Platelet attachment to hydrogels 
Platelet attachment was used as an initial measure of thromboresistance of the new 
hydrogel formulations. 10% PEG(3.4k)DA and 20% PEG(3.4k)DAA-NVP hydrogels were soaked 
for 3 days prior to cell seeding to remove any uncrosslinked NVP. Circular hydrogel specimens 
were punched from the hydrogel slabs and placed in a 48 well plate. Platelets were isolated from 




centrifuged at 990 rpm for 15 minutes to isolate the protein rich plasma (PRP) layer. The PRP 
layer was removed and prostacyclin was added at 10 µL/mL and centrifuged again at 1500 rpm 
for 10 min to form a platelet pellet. The pellet was resuspended in CGS buffer for washing and 
centrifuged again at 1500 rpm for 10 min. The platelets were then resuspended in Tyrode’s buffer 
at half the original volume of PRP. Sudan B Black solution (5% in 70% ethanol) was added to the 
platelet solution at a 1:10 ratio for 30 minutes at room temperature. The stained platelets were then 
washed with PBS 3 times by resuspending the pellet in PBS then centrifuging at 1500 rpm for 8 
min. Platelets were counted and resuspended at a concentration of 10 x 106 platelets/mL in sterile 
PBS. 500 µL platelet suspension was added in each test well, and platelets were allowed to adhere 
to substrate for 30 min at 37°C on a shaking incubator. Gels were transferred to new wells and 
washed twice with PBS, then carefully placed into microcentrifuge tubes and bound cells were 
lysed with 150 μL DMSO for 15 min at room temperature. 150 μL of PBS was added to each 
sample and the solution moved to a cuvette for reading on a spectraphotometer (400-650 nm, 
SpectraMax M2, Molecular Devices). 
4.2.9 Fabrication of multilayer vascular graft composites 
A 25 wt% solution of Bionate® (DSM) in dimethylacetamide was electrospun with a flow 
rate of 0.5 ml/hr through a blunted 20G needle. The rotating mandrel for collection was coated in 
a PEG sacrificial layer and placed 50 cm from the needle tip. A voltage of 15 kV was applied to 
the needle and a -5kV voltage was applied to the rotating mandrel. The rod and mesh were allowed 
to soak for 1 hour in water to dissolve out the sacrificial PEG layer, and the mesh sleeve was cut 
into 4 mm long sections. Electrospun mesh sleeves were then taken through a graded ethanol/water 
soak (70%, 50%, 30%, and 0%; 30 minutes each) to ensure hydration and penetration of the 




meshes were then placed in a cylindrical mold with an inner glass mandrel (3 mm OD). Hydrogel 
solutions were pipetted between the mandrel and the hydrated mesh (4 mm ID) and crosslinked 
with UV light for 6 minutes in a custom-built UV box. 
4.2.10 Accelerated hydrolytic degradation of hydrogel coatings 
Hydrolytic degradations of the hydrogels were first compared in accelerated degradation 
conditions of 50 mM NaOH at 37°C. 8 mm punches were taken from hydrogel slabs after swelling 
overnight and put under vacuum overnight. Dry weights were recorded, and the hydrogel punches 
were swollen in water for 1 hour before weighing to determine the swelling ratio. The gels were 
then transferred to their respective conditions. Swelling ratio (Q) was calculated as Ws/Wd. 
Swollen weights were measured once a day for accelerated degradation of 10% PEG(3.4k)DA, 
and PEG(3.4k)DAA conditions were measured once a week. Compressive modulus was also 
recorded at these time points, as described previously. 
To evaluate the hydrolytic degradation resistance of the vascular graft composites, 
multilayer vascular grafts were fabricated with either PEG(3.4k)DAA-NVP or PEG(3.4k)DA 
precursor solution. The composites were cut into 1cm long sections and incubated in the conditions 
described above for accelerated hydrolytic degradation. Degradation was measured as a change in 
luminal diameter. Pictures of the luminal diameter were acquired using a stereoscope (National 
Optical) and the diameter was measured using ImageJ software. 
4.2.11 Bioreactor whole blood study of platelet adhesion of multilayer grafts 
The thromboresistance of the multilayer graft was assessed by flowing fresh, heparinized 
porcine whole blood (Lampire Biological Laboratories) through the lumen of the grafts for 
extended time periods in a bioreactor. Multilayer grafts with PEGDA or PEG-NVP hydrogel 




chambers and fixed into place using sterile nylon thread. Segments of an ePTFE vascular graft 
control (GORE-TEX® Stretch Vascular Graft ST04015A) were fitted onto remaining graft ports 
(n = 4). Prior to the onset of flow, the blood was exposed to 10 µM mepacrine for 30 minutes at 
37°C to fluorescently label associated platelets. Samples were perfused with heparinized porcine 
whole blood for three hours at a flow rate of 100 ml/min/construct generated by a peristaltic pump 
(Masterflex L/S 07528-30). Grafts were then dismounted from the graft ports and gently rinsed 
twice with PBS followed by exposure to 10% neutral-buffered formalin.  Subsequently, the 
constructs were cut into two halves using fine-tipped surgical scissors, with the dissection plane 
slicing the length of each graft.  Half of each construct was allocated for fluorescence imaging of 
adherent platelets, and the remaining half was processed for quantitative assessment of platelet 
adhesion to the graft lumen. Fluorescence images of platelet adhesion were obtained utilizing a 
Zeiss Axiovert 200M microscope with a FITC filter set (ex/em 470nm/515nm) and a 20X 
objective. To quantitatively assess platelet adhesion, the lumen of graft sections were rinsed 3 
times with 200 μL of lysis buffer (100 mM TRIZMA-Base, 500 mM LiCl, 10 mM  EDTA, 1% 
LiDS, 5 mM dithiothreitrol). This lysis buffer was collected and associated mepacrine was 
measured spectrophotometrically (Biotek Synergy HTX plate reader) utilizing a FITC filter set. 
Sample concentrations were determined relative to a standard curve and then normalized to the 
luminal surface area of the processed graft section. 
4.2.12 Hydrogel particulate capture after suturing composites in ex vivo model 
Vascular graft composites, fabricated as described above, were made with either 
PEG(3.4k)DAA-NVP or PEG(3.4k)DA precursor solution (n = 4). Porcine carotid arteries were 
acquired from Lampire Biological Laboratories (Pipersville, PA) and used within 48 hours of 




grafts. Sham suturing was performed by suturing two carotid artery sections together using 7-0 
proline sutures with a tapered needle (Ethicon). The sutured grafts and sham were then placed in 
a flow loop under physiological pressures (80 mmHg to 120 mmHg) for 30 minutes to further 
dislodge any hydrogel particulates created during suturing. The flow buffer was collected and 
filtered for particulates 200μm or larger that were then counted manually. The remaining unfiltered 
particulates were counted using a Chemtrac particle counter (Atlanta, GA). Grafts were then 
sectioned to visually inspect suture line damage. 
4.2.13 Statistical analysis 
The data are displayed as mean ± standard deviation for all measurements with the 
exception of cell adhesion that is presented as mean ± standard error of the mean. An analysis of 
variance (ANOVA) comparison was used for multiple composition comparisons with a Tukey’s 
multiple comparison test to analyze the significance of the data. Comparisons in which there are 
only two compositions were compared using a student’s t-test. Linear trends were tested by 
determining if the slopes of the best fit lines were statistically non-zero using the linear regression 
function of GraphPad. All tests were carried out at a 95% confidence interval (p<0.05). 
4.3 Results 
4.3.1 Suture-induced damage in hydrogels 
Several hydrogel compositional variables were tested, molecular weight (10kDa, 6kDa, 
3.4kDa), crosslinker (10%, 20% 4-arm PEG acrylate), and polymer concentration (3.6, 7.2, 10, 20, 
30%), in an attempt to identify a correlation between gel mechanical properties and suture-induced 
damage. Despite the broad range of tensile properties, hydrogel particulates were detected in all 
PEGDA hydrogels when a suture needle was passed through the hydrogel slabs, Figure 4.3A. 




modulus, tensile strength, or elongation, Figure 4.4. In contrast, copolymerization with NVP 
resulted in a marked decrease in the total number of dislodged particles in all compositions of 
PEGDA hydrogels tested, Figure 4.3B. Additional mechanical testing of fracture toughness using 
a single edge notch tensile test identified a marked increase in fracture toughness in PEGDA-NVP 
hydrogels (Figure 4.3C). The force required to propagate the notch across the hydrogel was 
increased for all PEGDA-NVP compositions and correlated strongly with decreased suture-




Figure 4.3: A) Images of particles dislodged during suturing for both PEG(3.4k)DA and 
PEG(3.4k)DA-NVP hydrogel compositions. Black arrows indicate dislodged particles. B) Effect 
of incorporating NVP into 10% PEGDA hydrogels on suture damage resistance. C) Defect 
tolerance assessed by fracture toughness. D) Correlation of reduced particle generation during 
suturing with increasing fracture toughness. All data represents average ± standard deviation of 






Figure 4.4: A) Images of particles dislodged during suturing for both PEG(3.4k)DA and 
PEG(3.4k)DA-NVP hydrogel compositions. Black arrows indicate dislodged particles. B) Effect 
of incorporating NVP into 10% PEGDA hydrogels on suture damage resistance. C) Defect 
tolerance assessed by fracture toughness. D) Correlation of reduced particle generation during 
suturing with increasing fracture toughness. All data represents average ± standard deviation of 
n=6. The * represents a significant difference between groups with and without NVP (p<0.05).  
 
 
4.3.2 Effect of NVP concentration in PEGDA gels 
The effect of NVP concentration on the suture damage and compressive modulus of the 
PEGDA gels was tested (Figure 4.5).  The number of dislodged hydrogel particles decreased as 
increasing amounts of NVP were incorporated with particles ultimately eliminated with 54 moles 
of NVP added to the precursor solution for every 1 mole of PEGDA in solution, Figure 4.5A. A 




with increasing amounts of NVP, Figure 4.5B. In order to match the original compressive 
modulus, the polymer content was decreased to 7.2% PEG(3.4k)DA-NVP 1:54, which resulted in 










Figure 4.5: Effect of increasing NVP content in 10% PEG(3.4k)DA hydrogels on (A) defect 
tolerance and (B) compressive modulus. C) Matching modulus of the 10% PEGDA with the 
PEGDA-NVP formulation by decreasing PEGDA content. Data represents average ± standard 
deviation of n=6. The * represents a significant difference from the PEGDA Control, the ǂ 
represents significant difference from the control and PEGDA:NVP 1:12, and the # represents 
significant difference from all other groups (p<0.05) in ANOVA with Tukey’s multiple 








4.3.3 Evaluation of PEGDAA-NVP hydrogel as a candidate luminal layer 
Following identification of a method to enhance resistance to suturing damage of PEG-
based hydrogels, additional testing was performed to identify and evaluate a candidate hydrogel 
composition for use as the luminal layer of the multilayer grafts. Previous studies have 
demonstrated favorable cell adhesion and migration on the 10% PEG(3.4k)DA hydrogels and 
enhanced hydrolytic stability of PEGDAA hydrogels.54,86,125 In an effort to match the physical 
properties and biostability of these previous compositions, a new 7.2% PEG(3.4kDa)DAA-NVP 
was fabricated and tested in comparison to the 10% PEG(3.4kDa)DA hydrogel. The PEGDAA-
NVP formulation displayed comparable compressive modulus and swelling as the PEGDA control 
with an increase in defect tolerance as indicated by the elimination of suture-induced particles 
generation, Figure 4.6. Biostability of the PEGDAA-NVP was then assessed using accelerated 
hydrolytic testing. No significant difference in the equilibrium swelling ratio of the PEGDAA-




Figure 4.6: Matching swelling (A) and compressive modulus (B) between the original 10% 
PEG(3.4k)DA formulation and the damage-resistant 7.2% PEG(3.4k)DAA + 1:54 mol NVP 
hydrogel. C) Effect of decreasing polymer content and adding NVP to improve the defect tolerance 
of the hydrogel. Data represents average ± standard deviation of n=6. The * represents a significant 





Thromboresistance is another critical property to the success of any blood contacting 
material and was previously established in the original PEGDA hydrogel coating.86 As an initial 
assessment that thromboresistance was retained in the new composition, static platelet attachment 
was assessed on PEGDAA-NVP hydrogel slabs. A synthetic graft, ePTFE, served as a clinical 
control and displayed significant platelet attachment, 10.3 ± 4.9 platelets/cm2. In contrast, a 
statistically significant decrease in platelet attachment was measured on both the original PEGDA 
(1.5 ± 1.3 platelets/cm2) or new PEGDAA-NVP (0.47 ± 0.49 platelets/cm2) hydrogels. There was 
no significant difference between the PEGDA or PEGDAA-NVP suggesting that altering the 
hydrogel formulation to improve defect tolerance had limited impact on platelet attachment.  
Finally, the ability to confer bioactivity to the PEGDAA-NVP hydrogels was evaluated by 
incorporating acrylate-functionalized collagen and assessing endothelial cell adhesion. BAEC 
attachment studies demonstrated a statistically significant increase in cell attachment and cell 
spreading with collagen incorporated compared to the hydrogel controls. No significant 
differences were measured between PEGDA or PEGDA-NVP hydrogel compositions in either 
number of cells adhered (100 ± 6 cells/mm2 and 94 ± 6 cells/mm2) or cell spreading (942 ± 22 
μm/cell and 762 ± 35 μm/cell), respectively (Figure 4.7). Following these favorable results, this 





Figure 4.7: A) The effect of hydrogel composition on cell adhesion. Scale bar = 100µm. B) 
BAEC attachment on both compositions with incorporated functionalized collagen. C) BAEC 
spreading on both compositions with incorporated functionalized collagen. Data represents 
average ± standard error of n=4. The * represents a difference between groups with and without 
collagen (p<0.05), and the # represents a significant difference from all others (p<0.05) in 
ANOVA with Tukey’s multiple comparison test.  
 
 
4.3.4 Evaluation of the multilayer vascular graft 
Multilayer vascular grafts were fabricated with the new defect-tolerant hydrogel 
composition (7.2% PEG(3.4kDa)DAA-NVP) and grafts were evaluated for biostability, 
thromboresistance, and suture-induced damage in comparison to the previous hydrogel 
composition (10% PEG(3.4 kDa).86 In order to assess the effects of hydrogel degradation and 
subsequent swelling on the hydrogel luminal layer, accelerated hydrolytic degradation was 
performed on composite grafts with either PEGDA or PEGDAA-NVP inner layers. The PEGDA 
luminal diameter decreased by the first day, and continued to decrease until eventually the PEGDA 
inner layer delaminated from the outer layer and achieved total dissolution by day 5. The 
PEGDAA-NVP inner layer demonstrated no change in the luminal diameter over the course of 28 





Figure 4.8: A) The effect of hydrogel composition on hydrolytic degradation rate. B) Luminal 
diameter changes for both compositions; ruler scale is 1mm. Data represents average ± standard 
deviation of n=4. 
 
 
Given the low platelet attachment on hydrogels under static conditions described above 
(Figure 4.9A), the multilayer vascular grafts were assessed with whole blood in a pulsatile flow 
bioreactor. The results of the whole blood attachment studies closely mirror the trends in the 
platelet attachment study. Low platelet attachment on the PEGDA (0.08 ± 0.02 platelets/cm2) and 
PEGDA-NVP (0.1 ± 0.05 platelets/cm2) composites was observed and the results were statistically 






Figure 4.9: A) The effects of hydrogel composition on static platelet adhesion. B) The effects of 
hydrogel composition on bioreactor whole blood platelet attachment. Scale bar = 100µm. C) 
Representative images of platelet attachment from the whole blood study. Data represents 
average ± standard deviation of n=4. The * represents a significant difference from ePTFE 
control (p<0.05) in ANOVA with Tukey’s multiple comparison test. 
 
 
Finally, an ex vivo flow loop model was used to provide a more rigorous simulation of the 
implantation procedure and assess particle generation following suturing of the multilayer grafts, 
Figure 4.10A. The number of dislodged hydrogel particles were counted in both the storage 
solutions of the sutured grafts and the solutions collected from the flow loop set up. Particulates 
were identified in all solutions except the sham control. More hydrogel particulates were identified 
in the storage containers of both formulations than in the flow solutions. There was also a 
statistically significant increase in particles detected in the solutions of the PEGDA composition 
than in the PEGDAA-NVP composition, Figure 4.10B. Upon investigation of the sutured ends of 









Figure 4.10: A) Composite graft sutured to excised porcine carotid artery segments and diagram 
of flow loop. B) Effect of composition on the number of particles captured in the flow loop after 
in vitro suturing. C) Sectioned grafts demonstrating hydrogel suture line damage after in vitro 
suturing. Data represents average ± standard deviation of n=4. The # represents a difference from 
all others (p<0.05) in ANOVA with Tukey’s multiple comparison test. 
 
 
Additional analysis of the graft indicated damage to the center of both sets of grafts and attributed 
to forceps gripping of the graft during the suturing procedure. Composite grafts with thinner 





Figure 4.11: A) Suturing of grafts to porcine carotid arteries. Black arrow indicates gripping 
area. B) Sectioned grafts after suturing demonstrating hydrogel damage. C) Effects of hydrogel 




The observed suture-induced damage of the hydrogel coating after implantation of the 
multilayer vascular graft created a clear need for a hydrogel with increased defect tolerance. 
Hydrogel particulates from suture-induced damage can result in embolisms downstream leading 
to severe complications and morbidity. To generate a new hydrogel coating that could be used 
clinically without risk of embolism, traditional hydrogel variables (molecular weight, 
concentration, crosslinker) were investigated to first identify a correlation between gel mechanical 
properties and suture-induced particle generation. Despite the large ranges investigated for 
modulus (6 kPa to 66 kPa), tensile strength (11 kPa to 43 kPa), and elongation (7% to 314%), no 






The mechanical property that could be correlated with defect tolerance was fracture 
toughness as measured by a single edge notch test. The energy required for crack propagation was 
a better predictor of hydrogel defect tolerance and particle generation during suturing. Increased 
fracture toughness was achieved in the PEG-based hydrogels through copolymerization with NVP 
and attributed to the additional hydrogen bonding sites available upon NVP incorporation. 
Although there are several possible secondary interactions, one such is water bridging between the 
carbonyl of the NVP amide and the carbonyls of the ester of PEGDA or amide of PEGDAA, as 
diagramed in Figure 4.12. It has been demonstrated that an increase in secondary force interactions 
between polymer chains requires greater energy to initiate crack propagation, and this higher 
initiation energy creates a higher defect tolerance in the crosslinked polymer.162,164 For our system, 
the addition of NVP to the PEG-based hydrogels was hypothesized to reduce suture-induced 
damage by introducing sacrificial, hydrogen bonds that dissipate initial crack energy and 





Figure 4.12: The effect of adding n-vinyl pyrrolidone to PEGDA hydrogels on defect tolerance. 
Fracture energy is increased by introducing sacrificial bonds via increased hydrogen bonding, 
thereby increasing defect tolerance. The sacrificial hydrogen bonds are created by water bridging 
of the carbonyl of the PEGDA ester and the carbonyl of the NVP amide groups. 
 
 
In order to achieve incorporation and total elimination of dislodged hydrogel particulates, 
relatively large amounts of NVP (54 moles to 1 mole of PEGDA) must be added to the hydrogel 
precursor solution. During formation of the crosslinked hydrogel network, three simultaneous 
reactions take place upon UV irradiation of the pre-cursor solution: homopolymerization of the 
acrylates in PEGDA, homopolymerization of the vinyls in NVP, and copolymerization of the 
acrylates and vinyls. According to an assay for the detection of tertiary amines developed by El-
Rabbat et al., approximately 16 ± 9% of the NVP added is incorporated into the hydrogel network. 
The high sol fraction (Figure 4.13) also supported a low level of NVP incorporation into the 
network. This result is expected given that the propagation rate (kp) is much higher for acrylate-
acrylate reactions (2.165 x 104 L/mol·s) then for acrylate-vinyl reactions (0.101 x 104 L/mol·s). 




due to the limited availability of the acrylate groups for reaction. Therefore, large molar ratios of 




Figure 4.13: Effect of leaching PEGDA-NVP gels on sol/gel. 
 
 
Although increasing amounts of NVP increased defect tolerance, it also increased the 
compressive modulus of the resulting hydrogel, Figure 4.5.  It was hypothesized that the increase 
in compressive modulus and decrease in swelling ratio was due to an overall increase in polymer 
concentration in the final gel and corollary decrease in mesh size. However, when overall polymer 
content (PEGDA and NVP) is kept constant, there is a decrease in compressive modulus and 
increase in swelling, likely due to the disruption of network formation by NVP, Supplemental 
Table 1. Based on this finding, modulus was reduced to match the PEGDA control by decreasing 
the PEGDA concentration of the hydrogel. The resulting hydrogel maintained a similar defect 
tolerance and similar swelling ratio as the PEGDA hydrogel control. This suggests that the 





In addition to suture damage resistance, it is important the hydrogel coating is resistant to 
hydrolytic degradation to ensure it remains intact for the lifetime of the graft. In order to 
accomplish this, the formulation was changed from a PEGDA based hydrogel that contains ester 
linkages to PEGDAA that contains more hydrolytically stable amide linkages. Previous work in 
our lab has demonstrated the in vitro and in vivo hydrolytic stability of the PEGDAA hydrogels.86 
The PEGDAA-NVP displayed a similar resistance to hydrolysis as evidenced by the accelerated 
hydrolytic degradation study. Stability of the graft inner layer is critical to supporting the 
endothelial cell layer as well as preventing occlusion of the graft due to increased swelling of the 
hydrogel, Figure 4.8. 
Following confirmation that the defect-tolerant hydrogel formulation maintained 
bioactivity and thromboresistance, a preliminary ex vivo suturing study was performed by suturing 
the composite graft to excised porcine carotid arteries. Preventing hydrogel damage is critical to 
the clinical relevance of the multilayered graft, as dislodged hydrogel particulates can act as emboli 
in the vascular system, and cause downstream heart attacks and strokes. This study demonstrated 
that significantly fewer particles are dislodged from the PEGDAA-NVP hydrogel coated graft than 
from the PEGDA hydrogel coated graft, Figure 4.10. Upon investigation of the suture line, the 
PEGDAA-NVP hydrogel appeared intact whereas the PEGDA hydrogel displayed severe damage, 
Figure 4.1C. The dislodged particles in the PEGDAA-NVP hydrogel detected in the storage 
solutions were attributed to damage of the hydrogel layer at the middle of the graft due to gripping 
with forceps to stabilize the graft during suturing (Figure 4.11). We have confirmed that the 
gripping damage can be mitigated by using thinner hydrogel coatings in the graft composites. This 






Our previous work developing small diameter vascular grafts led to the discovery of the 
unique problem of particles dislodged from the hydrogel luminal layer during suturing. To address 
this problem, a new PEGDAA-NVP hydrogel with improved fracture toughness was developed. 
Increased defect tolerance was achieved through the introduction of sacrificial, hydrogen bonds 
that enabled suturing of the multilayer vascular graft without particle generation. It was also 
demonstrated that this modification resulted in no significant increase in thrombogenicity or 
change in bioactivity compared to a well-characterized PEGDA hydrogel. Therefore, we have 
successfully addressed the need for a suture-damage resistant hydrogel coating for use in small 
diameter vascular grafts and highlighted the need for testing the generation of dislodged particles 
in blood contacting materials. Future work will build upon the current research by testing the initial 
thromboresistance and long-term stability of the multilayered vascular graft with the new hydrogel 










The work presented here improves many aspects of the multilayer graft, creating potential 
for safe clinical implementation and long-term patency. Through elucidation of fundamental 
biological and material relationships, improvements have been made to control cellular 
interactions, outer layer mechanical properties, and suture damage resistance of the hydrogel inner 
layer. Not only can these fundamental relationships be applied to the multilayer graft, they have 
the potential to optimize and improve many cardiovascular devices and constructs.  
The first section of this work is dedicated to elucidating integrin-mediated hemostatic 
control in endothelial cells for improved cellular interactions with the graft inner layer. Endothelial 
cells have previously been shown to alter expression of hemostatic regulators based on their local 
substrate, but little work has been done to investigate the hemostatic effect of individual integrin 
binding in endothelial cells. We first investigated the relative expression of select integrins 
commonly used for attachment by endothelial cells to the basal lamina (α1β1, α2β1, α5β1, αvβ3). 
Then, utilizing integrin antibody blocking, we demonstrated that we can target these integrins 
using bioactive hydrogels enriched with common extracellular matrix proteins and designer 
collagens. We also showed that hemostatic regulator expression in endothelial cells and the 
correlating functional assay of platelet adhesion and activation can be modulated by specific 
integrin targeting. This work demonstrates that by using designer collagen programmed to target 
α1β1 and α2β1, we can limit endothelial cell thrombogenicity while promoting endothelial 




regulation through endothelial cell integrin targeting can be used to make thromboresistant 
coatings on many types of blood-contacting devices.  
The next section describes the process of elucidating the intrinsic relationship between 
graft compliance and the onset of intimal hyperplasia. Intimal thickening is a common failure mode 
for synthetic vascular grafts, causing reocclusion at the distal anastamosis. This relationship has 
been previously difficult to elucidate due to confounding factors, such as differences in material 
chemistry that can affect cellular interactions between grafts of different compliances. By utilizing 
electrospinning to fabricate polyurethane grafts, we were able to create grafts of increasing 
compliance without altering graft material chemistry. This allowed for isolation of compliance as 
the single influencer of change in the system. Grafts sutured to carotid arteries were cultured for 
two weeks and interrogated for early markers of intimal hyperplasia. Changes in early markers for 
intimal hyperplasia that indicate smooth muscle cell proliferation and migration toward the lumen 
were correlated to changes in wall shear stress as predicted by a computational model of the sutured 
grafts. Using these systems, we were able to link poor compliance matching to early markers of 
intimal hyperplasia. This is the first definitive study to identify this relationship, and this bioreactor 
system is the first presentation of a rapid screening method for small diameter vascular grafts.  
The last chapter is dedicated to the discovery and characterization of a suture-damage 
resistant hydrogel to implement as the inner layer of the multi-layer graft. Initial studies utilizing 
the multilayer vascular graft found that pieces of the PEGDA hydrogel were dislodged during 
suturing, creating pseudo-embolisms that can put patients at risk for stroke. In order to address this 
limitation, we identified a hydrogel formulation and key properties that eliminate particles 
dislodged during suturing. By introducing sacrificial hydrogen bonds in the hydrogel formulation, 




the hydrogel. Identification of this relationship allows for further hydrogel design and 
optimization. We demonstrated that introduction of these sacrificial bonds does not affect 
bioactivity or thromboresistance, retaining properties similar to those of the original hydrogel 
formulation. By creating a hydrogel layer with suture damage resistance, we have rendered the 
graft safe for implantation.  
With this work, the new vascular graft has 1) improved cellular interactions that promote 
thromboresistance upon endothelialization, 2) improved compliance matching that has been 
demonstrated in an ex vivo organ culture model to limit early markers of intimal hyperplasia, and 
3) improved hydrogel mechanics for a suture damage resistant hydrogel that is requisite for 
implantation. Overall, this work serves to enhance not only the vascular graft, but provide 
fundamental insights into material design that can be applied to a number of devices and platforms.  
5.2 Significance of Work 
Elucidation of endothelial cell hemostatic regulation with integrin-targeting hydrogels 
 The aim of many blood contacting devices such as vascular grafts is to promote 
endothelialization to limit thrombogenicity of the material. By elucidating the individual and 
combinations of integrins that promote not only adhesion and migration but thromboresistance in 
endothelial cells, we can optimize biomaterial platforms to target these specific integrins. 
However, few studies have isolated individual integrin binding for the study of their effects on 
endothelial hemostasis. We established a novel integrin targeting platform using bioactive 
hydrogels and designer collagens that allows for simple evaluation of this targeting. This is the 
first reported use of this platform to study integrin targeting effect of hemostasis in endothelial 
cells. Using this novel platform, we identified integrin combinations that drive endothelial cells 




research with few reports of individual effects of integrins on endothelial cell hemostatic 
regulation. Overall, this work provides technology and methods for promoting endothelialization 
of blood-contacting surfaces through priming endothelial cells with a thromboresistant phenotype. 
 
Elucidating the role of graft compliance mismatch on intimal hyperplasia using an ex vivo organ 
culture model 
 Although intimal hyperplasia, a prominent failure mode of small diameter vascular grafts, 
has long been linked to poor compliance matching, there is no single study that definitively links 
the two. In the work presented here, we offer the first definitive study to elucidate this intrinsic 
link. In order to do so, we provide the first known description of grafts fabricated with increasing 
compliance over a wide range without changing material chemistry or fabrication method. The 
graft compliances range from the clinical standard of ePTFE (low compliance) to compliance of 
the carotid artery (high compliance, a good native arterial match). Importantly, we confirmed that 
the high compliance graft that matches compliance of the carotid artery maintains a high burst 
pressure and suture retention strength. This is the first known report of such a synthetic graft. Using 
this new library of graft compliances, we established an ex vivo organ culture model and 
computational model to elucidate the definitive link between graft compliance and the onset of 
intimal hyperplasia. Arteries sutured to low compliance grafts exhibited increased staining for 
smooth muscle cell proliferation and migration, important early markers of intimal hyperplasia. 
This link of poor compliance matching causing early markers of intimal hyperplasia contributes 
significantly to the fields of cardiovascular disease and cardiovascular graft design. Not only did 




potential rapid screening method for small diameter vascular grafts using the ex vivo organ culture 
system and computational model.  
 
Introduction of sacrificial bonds to hydrogels to increase defect tolerance during suturing of 
multilayer vascular grafts 
 The need for investigation of a suture damage resistant hydrogel emerged from a practical 
need and an absence of any mention of such a hydrogel in literature. In pursuing a suture damage 
resistant hydrogel, we identified fracture toughness as a key factor in predicting suture damage 
resistance. In order to eliminate particles dislodged during suturing, hydrogels required an increase 
in fracture toughness, accomplished by the introduction of sacrificial bonds. In this work, we 
present a novel hydrogel formulation that is suture damage resistant without affecting bioactivity 
or thrombogenicity. This hydrogel is ideal for the multilayered graft, and it can be applied to many 
other systems and soft tissue applications requiring suturing. Importantly, we identified a key 
factor for developing suture damage resistance in soft hydrogels that can be applied to many 
different hydrogel formulations. 
 
5.3 Challenges and Future Work 
 The work presented here provides significant advancements in the development of the 
multilayer graft, but extensive investigation remains to be performed in order to make the graft a 
useful clinical product. In this work we have provide important insight into the influence of integrin 
attachment on endothelial cell hemostatic regulation. However, this regulation in endothelial cells 
is influenced by more than just the underlying ECM. These cells receive cues from many other 




work will need to determine which factors or factor combinations dominate endothelial 
thromboresistance for optimal biomaterial design. This could be accomplished by assessing the 
hemostatic regulation of endothelial cells under shear stress by applying flow to the system. The 
effects of varying substrate stiffness could be assessed by increasing and decreasing the 
compressive modulus of the bioactive hydrogels over a broad range. The ultimate determination 
will be the evaluation of the endothelial cell behavior in vivo on various platforms, as it is difficult 
to recapitulate all of these factors in a single in vitro set up. Not only will their hemostatic 
regulation be important to monitor, but the efficiency of the coating of the hydrogel inner layer 
has yet to be evaluated. If the endothelialization process proves to be slow in the in vivo evaluation, 
further modification of the inner layer may be required, such as rolling capture of endothelial 
progenitor cells to accelerate the endothelialization process.   
We have established a significant correlation with the ex vivo bioreactor system between 
compliance matching and early markers of intimal hyperplasia, but further confirmation and 
correlation is required with an in vivo study. To validate the study results, we need to evaluate the 
presence of early markers of intimal hyperplasia in grafted arteries at 2 weeks in vivo. Longer time 
points will be required to confirm that the early markers of intimal hyperplasia do indeed lead to 
development of intimal thickening and occlusion in vessels grafted to low compliance grafts. In 
vivo evaluation is also required of the high compliance graft to demonstrate that the accelerated 
oxidative degradation study correlates to in vivo results.  
We have developed the new inner layer hydrogel formulation that resists suture damage 
and compression damage, but it is susceptible to disruption by graft torqueing. In order to address 
this issue, it is possible to introduce more hydrogen bonding while increasing polymer chain length 




increased torqueing damage resistance also must be evaluated clinically to ensure that forces 
recapitulated in the lab assessment of torqueing are representative of what is actually applied by 
the surgeons performing the grafting procedure. Ultimately, this new layer must also be evaluated 
in vitro for possible changes in bioactivity and thrombogenicity as well as in vivo assessment for 
efficacy as a viable inner layer. Overall, in vivo porcine models would confirm 1) that inner layer 
promotes endothelialization while limiting thrombogenicity, 2) that the outer layer retains its 
mechanical properties, and 3) that increased compliance matching resists intimal hyperplasia.  
Although there is substantial evaluation and development yet to be performed in the 
multilayered graft, the work presented here has advanced the graft toward the goal of being an off-
the-shelf small diameter synthetic vascular graft that has initial and sustained thromboresistance 
while limiting intimal hyperplasia. First, we provide details of the endothelial cell interactions with 
the hydrogel inner layer that can be further tailored to tune thromboresistance. Then we provide 
definitive evidence for the need for compliance matching to limit intimal hyperplasia and 
demonstrate fabrication of a graft with a high compliance with requisite burst pressure and suture 
retention strength. Finally, we have developed a suture damage resistant hydrogel that can be 
further modified for inner layer improvement. These improvements and elucidation of 
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APPENDIX I  
DESIGNER COLLAGEN PRODUCTION, CHARACTERIZATION, AND OPTIMIZATION 
A.1 Introduction 
Streptococcal collagen-like proteins, or Scl2, are recombinant proteins that mimic the triple 
helical structure of collagen but do not require post-translational modification for helix 
formation.121 Although they mimic the structure of collagen, the Scl2 proteins are devoid of the 
native binding sites associated with collagen.121 Therefore, the bioactivity of the Scl2 protein can 
then be customized by site-directed mutagenesis to introduce peptide sequences for specific cell 
surface receptor targeting.122 For example, the collagen-derived peptide binding sequence 
GFPGER targets the integrins α1β1 and α2β1 and has been incorporated into Scl2 to tailor 
bioactivity.122,123 Scl2 proteins with this targeting sequence are known as Scl2GFPGER proteins, and 
the binding of integrins to this peptide sequence is strengthened by the triple helical structure of 
the Scl2GFPGER protein.124 This protein is naturally thromboresistant, even with the integrin 
targeting sequence, making it ideal for incorporation into the multilayer vascular graft to promote 
endothelialization.86 Although production of this protein can be simple and high through-put with 
recombinant expression in E. coli, there have been inconsistencies in the protein batches that were 
discovered through irregularities in cell binding to the protein in hydrogels. Batch variability must 
be reduced in order to have consistent results in investigating the protein’s effects and to make the 
production process appropriate for commercialization. Reducing batch variability required 
identification of the factors that affect the structure and bioactivity of the protein. The work 
presented here describes the production methods and processes that can affect the protein structure 





A.2 Scl2GFPGER Evaluation 
Scl2GFPGER protein structure and stability are key to its function of binding the targeted 
integrins α1β1 and α2β1.122,123 The structure of the protein can be characterized several ways, 
including molecular weight and monomer content by SDS-PAGE, presence and tightness of the 
triple helix by circular dichroism, and aggregation by solubility assessment. The stability of the 
protein can be evaluated by measuring the melting curve, again using circular dichroism. Each of 
these measures may be useful predictors of the success of the batch in promoting cell binding. 
However, the protein functionality is ultimately assessed by cell adhesion on protein coats and 
Scl2GFPGER enriched hydrogels, depending on the intended application. For Scl2GFPGER 
incorporated into 3D structures, hydrogel evaluation is especially important, as the surface 
presentation of the protein is different than that of a protein coat.  
A.2.1 Scl2GFPGER Molecular Weight and Monomer Content 
Although the structure of the Scl2GFPGER protein is similar to that of collagen, the protein 
is only roughly one third of the size of collagen, about 35 kDa compared to collagen’s 110 kDa. 
The molecular weight can be assessed using non-denaturing SDS-PAGE. The same gel can be 
used to assess monomer presence and content, giving an approximate indication of the fraction of 
the protein batch is in fact a true Scl2GFPGER protein with a stable triple helix. The bands indicating 





Figure A.1: Characterization of Scl2-2 protein monomer content and molecular weight using 
SDS-PAGE. Scl2 batches are compared between native conformation and denatured 
conformation. Native structure appears around 170kDa, and monomers appear around 34kDa. 
 
 
A.2.2 Scl2GFPGER Triple Helix 
 Although SDS-PAGE can indicate the fraction of the protein batch that is in a triple helical 
form based on the expected molecular weight, it cannot disseminate the tightness of the triple helix. 
This can be characterized use circular dichroism (CD). CD is a measure of the difference in 
absorption between the left- and right-handed light of circularly polarized light.165 CD is 
commonly used to characterize the secondary structure of proteins, with different peaks at various 
wavelengths indicating structures such as beta sheets and alpha helices. Examples of these 





Figure A.2: Representative CD spectra of various protein conformations. Adapted from 
Greenfield et al 2009. 
 
 
 The presence of a triple helix is indicated by a peak in the CD spectra at 220nm.166 The 
height of this peak can be a relative measure of the tightness of the helix. Additionally, the tightness 
of the alpha strand helices that make up the triple helix may have a relative measure by comparison 
of the shift in the valley of the peak around 200nm.167 An example of these comparisons and shifts 





Figure A.3: Representative CD spectra of Scl2-2. The peak at 220nm demonstrated the presence 
and tightness of the triple helix based on the relative height of the peak. The valley around 




A.2.3 Scl2GFPGER Aggregation and Solubility 
 Another assessment of the structure of the Scl2 protein is its solubility. In the production 
process of the protein, there are opportunities for the proteins to loosen its triple helix then entangle 
with other loosened proteins, creating irreversible protein aggregates in non-native 
conformations.168 These aggregates are theorized to preclude cell adhesion due to disruption and 
blocking of binding sites. Scl2 aggregates are visible in solution as they do not readily dissolve, 
especially when the protein is at a high concentration. Therefore the presence of aggregates can be 
identified by attempting to dissolve the protein. If aggregates of the protein are identified after 
protein isolation but before lyophilization, they can be “spun out” via centrifugation, leaving only 




In general, dissolution of the protein, similar to collagen, can be improved by the addition 
of salts and by altering pH.168,169 The ideal salt molarities and pH ranges to retain protein structure 
are ultimately determined by the overall charge of the protein.168 The salt ions can modulate the 
strength of the electrostatic interactions between charged groups in the protein that ultimately 
dictate the protein conformation.168,169 In studies examining the effects of neutral salts on the 
structure of collagen, it was shown that salts competitively reorganize the water involved in 
stabilizing the collagen helix, contributing to the triple helix stability.169 Use of buffers such as 
PBS can therefore contribute to the stability of the triple helices in solution. Although low pH has 
been demonstrated to increase solubility of collagen by loosening the structure, it has been 
previously demonstrated that low pH destabilized the triple helix of Scl2 proteins by shifting the 
melting curve dramatically (Figure A.4).124 Therefore, lowering pH can contribute to improved 
dissolution of Scl2 proteins within a specific range, but lowering the pH too far can decrease the 
melting point beyond practical levels. Another method to protect protein structure is the 
introduction of a stabilizer into solution. One such stabilizer is sucrose, and it protects protein 
structure by preventing unfolding through preferential surface exclusion, or negative binding. As 
the surface area of the protein increases, as is what occurs during unfolding, the protein is pushed 





Figure A.4: The melting temperature of Scl2 is lowered by lowering the pH of the solvent. From 
Mohs et al. 2007. 
 
 
A.2.4 Scl2GFPGER Stability 
 The overall thermodynamic stability of the Scl2GFPGER triple helix can be assessed by 
monitoring the denaturation in the triple helix in a neutral buffer over a temperature range to find 
the melting temperature. This can be accomplished with CD analysis by measuring the height of 
the peak at 220nm over the specified temperature range. The melting temperature of Scl2 proteins 
is typically observed around 35°C (Figure A.5), but batch variability or low pH of the solvent can 





Figure A.5: Representative CD spectra of the Scl2-2 melting curve. 
 
 
A.2.5 Cell Adhesion on Scl2GFPGER Protein Coats 
Protein structure and stability characterization can give clues as to the functionality of the 
protein, but protein batch success can ultimately only be tested via cell adhesion to determine its 
binding affinity. Using low protein concentrations (2-10µg per 96 well), well plates can be coated 
with the protein, blocked with BSA to limit non-specific binding, then exposed to cells to 
determine attachment differences between different proteins and batches.  
In order to assess Scl2GFPGER protein functionality with cell adhesion, the cells used in the 
adhesion study must present the targeted integrins, α1β1 and α2β1, in relatively high abundance. 
C2C12 cells are commonly used with induced overexpression of these integrins. Most endothelial 
cells also express these integrins, and these are the cells we commonly use in our studies. However, 
if there is ever a question of appropriate integrin expression, use of C2C12 cells is a method to 
ensure attachment is possible. Although there are observable differences in attachment between 
protein types, such as between the collagen and Scl2GFPGER shown below (Figure A.6), there is 
too much variability in the test to effectively determine differences between adhesion in batches 
that later arise when the protein is incorporated into a 3D matrix. Protein coat attachment is 









A.2.6 Cell Adhesion on Hydrogels 
 A more discerning test of Scl2GFPGER function is to incorporate it into hydrogels, where 
surface presentation is more random and perhaps less concentrated. The Scl2GFPGER protein is 
incorporated into 3D structures, as it cannot form 3D structures independently. In order to 
covalently incorporate the protein into a hydrogel, a common application in our lab, the protein 
must first by functionalized with a linker. Previous work has determined the optimal 
functionalization density for maximum cell adhesion without significant protein loss to be 0.1X, 
or functionalization of 10% of the lysines present in the protein.54 This previous work also 
demonstrated that FTIR spectra can be used to determine the relative functionalization of the 





Figure A.7: FTIR spectra of Scl2-2 and collagen functionalization with the PEG-based linker 
Acr-PEG(3500)-NHS. The functionalization increases from 10% of the available lysines (0.1X) 
to 100% of the available lysines (1X). The peak at 1110 represents the PEG backbone, and the 
peaks at 1650 represent the amines of the protein. Adapted from Browning et al 2013. 
 
 
 Cell attachment is performed as previously described.170 Briefly, once the protein is 
incorporated into the PEGDA hydrogel, it is soaked overnight with 3 PBS changes. Then the 
hydrogel slab is punched into rounds and placed into a 48 well plate. Cells are then seeded at 
10,000 cells/well, allowed to adhere for 3 hours, rinsed with PBS to remove non-adherent cells, 
and fixed with 3.7% glutaraldehyde. Hydrogel slab cell attachment provides a clear picture of 





Figure A.8: Endothelial cell adhesion on collagen and Scl2-2 hydrogels. 
 
 
A.3 Expression system effects  
Scl2GFPGER protein is produced through the recombinant expression of the protein in E. coli, 
as described previously.121 Briefly, E. coli are grown out in LB media until the absorbance 
measurement OD600 falls between 0.6 and 0.8. Then expression of the protein in the E. coli is 
induced by the addition of IPTG. After expression of Scl2GFPGER, the E. coli are spun down for 
collection (8000 rpm, 4˚C, 15 min) then frozen to encourage disruption of the bacterial membranes. 
The thawed E. coli are then sonicated or French pressed in order to release the cellular contents. 
The cellular waste is then removed via centrifugation (20000g, 4˚C, 30 min), and the Scl2GFPGER 
protein is then isolated using nickel columns. Different strains of E. coli can be used for protein 
expression, and they each have different effects on Scl2-2 protein structure.  
The Topp 3 system was used initially to express Scl2GFPGER. This system is characterized 
by considerable variability in protein production. In fact, the product is no longer manufactured 
due to concerns about the protein production consistency (REF). BL21 is the new recommended 
system and is thought to have more consistency between batches (REF). Yet another system, the 




with lower endotoxin levels could help limit the amount of post-process cleaning required for 
making the protein safe in animal studies. However, in switching to the Clear Coli system, the 
structure and stability of Scl2GFPGER is greatly affected.  
Characterization of the protein made using the Clear Coli system reveals high monomer 
content, a less stable triple helix, and lower cell attachment as compared to Scl2GFPGER made via 
expression in Topp 3 (Figure A.9). In the non-denaturing SDS-PAGE, there is an obvious band at 
around 40-55kDa in the Clear Coli Scl2GFPGER, indicating a denatured form of the Scl2GFPGER 
protein. Upon further investigation, we discovered that the melting temperature of Clear Coli 
Scl2GFPGER is much lower than that of the Topp 3 Scl2GFPGER, 32˚C and 37˚C, respectively. When 
the protein is incorporated into hydrogels, there is an obvious difference in cell adhesion, with 





Figure A.9: Comparison of Scl2-2 expression systems using protein characterization in SDS-
PAGE with lyophilized, non-lyophilized and functionalized, and functionalized and lyophilized 








A.4 LPS Removal Effects 
Lipopolysaccharides, or LPS, are endotoxins that are structural components of the outer 
cell membrane of all gram-negative bacteria, and they appear in the Scl2GFPGER proteins due to the 
expression method. Endotoxins elicit an immune response, therefore they must be removed for the 
protein to be used in animal models. There are several methods for LPS removal. In detergent 
removal, the protein is washed with Triton X-114 to degrade the LPS, followed by dialysis to 
remove the detergent .This is generally considered an efficient method of LPS removal with very 
little loss of protein. However, the Scl2GFPGER structure is sensitive to harsh detergents, and the 
protein tends to unfold, as shown in Figure A.10. This unfolding can increase the monomer content 
of the batch as well as create the opportunity for protein aggregation as discussed earlier.  
 Another method for LPS removal is column purification. An example of such a column is 
the Pierce High Capacity Endotoxin Removal Spin Column. The porous cellulose beads in the 
column have been surface modified with polylysine that has a high affinity for endotoxins. This 
removal method is much less damaging to the protein with little change in the protein structure 
and function. The column removal is also less efficient, however, and requires many passes 
through the column in order to reduce the LPS to acceptable levels for animal use. The many 





Figure A.10: Effect of detergent LPS removal on protein structure and monomer content. 
 
 
A.5 Globular Domain Removal Effects 
The Scl2GFPGER proteins are comprised of a rounded globular domain and a long 
collagenous tail, forming a lollipop structure. The globular domain has a diameter that is roughly 
3.9-6.4nm, and the collagen like tail is approximately 45.5nm long.121 Removal of the globular 
domain is thought to increase solubility of the Scl2GFPGER protein as well as lower any possible 
remaining immunological concerns, as the globular domain has more bacterial-specific peptide 
sequences that can be recognized as “non-self” by other animal species. Globular domain removal 
is achieved by enzymatic cleavage, and slightly reduces the molecular weight of the Scl2GFPGER 
protein. Removal of the globular domain does not appear to have large effects on the triple helix, 





Figure A.11: Comparison of Scl2-2 with and without the globular domain in CD for triple helix 
(A), CD for melting curve (B), and cell attachment (C). 
 
 
A.6 pH Effects on Conformation and Function 
Enzymatic cleavage of the globular domain can be performed in different pH conditions, 
depending on the enzyme used for cleavage. Typically we have used pepsin as the cleaving 
enzyme, and pepsin has optimum activity at a pH of 2.5. This pH can still alter Scl2GFPGER protein 
structure, similar to the detergent washes described above for LPS removal. Even small changes 
in protein conformation can affect binding affinity of targeted integrins on the cell surface.171### 
The enzyme has also shown to be effective at a pH of 4, and although the condition is still harsh, 
the effects of the low pH on the protein structure are hypothesized to be minimal enough to allow 






A.7 Conclusions and Future Work 
The work presented here demonstrates many ways to characterize Scl2 protein structure 
and function. Using various assessment tools, we can analyze protein monomer content and 
aggregation, triple helix formation and stability, and batch affinity for cell attachment. We have 
also identified several production and isolation processes that can affect Scl2 structure and 
function. Although there has been extensive characterization of the Scl2GFPGER protein structure, it 
is difficult to identify a single predictor of protein functionality in hydrogels. Without knowing the 
strongest predictor of protein batch success, batches cannot be effectively screened before use in 
hydrogels. This work, however, has created a system for possible discovery of that predictor.  
 The specific integrin targeting of Scl2GFPGER can be used to control cell fate through 
intracellular signaling initiated by integrin attachment. With the demonstrated potential for 
targeted binding and control, this protein has been used in many bioengineering applications, such 
as cardiovascular, orthopedic, and wound healing biomaterial design. Therefore, future 
optimization of Scl2GFPGER production is crucial for many applications in tissue engineering and 
biomaterial design. Future work with the Scl2 family of proteins will require identifying the best 
expression and isolation parameters to produce consistent batches of protein. Once batch 
consistency and functional predictability has been established, then fermenter scale up of the 
production process can increase batch yield. This would be ideal for commercialization and large 
experimental studies.  
